

CPC COOPERATIVE PATENT CLASSIFICATION

A HUMAN NECESSITIES

HEALTH; AMUSEMENT

A61 MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61K PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms [A61J 3/00](#); chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles [A61L](#); soap compositions [C11D](#))

NOTES

- This subclass covers the following subject matter, whether set forth as a composition (mixture), process of preparing the composition or process of treating using the composition:
 - Drug or other biological compositions which are capable of:
 - preventing, alleviating, treating or curing abnormal or pathological conditions of the living body by such means as destroying a parasitic organism, or limiting the effect of the disease or abnormality by chemically altering the physiology of the host or parasite (biocides [A01N 25/00](#) - [A01N 65/00](#));
 - maintaining, increasing, decreasing, limiting, or destroying a physiological body function, e.g. vitamin compositions, sex sterilants, fertility inhibitors, growth promoters, or the like (sex sterilants for invertebrates, e.g. insects, [A01N](#); plant growth regulators [A01N 25/00](#) - [A01N 65/00](#));
 - diagnosing a physiological condition or state by an *in vivo* test, e.g. X-ray contrast or skin patch test compositions (measuring or testing processes involving enzymes or microorganisms [C12Q](#); *in vitro* testing of biological material, e.g. blood, urine, [G01N](#), e.g. [G01N 33/48](#))
 - Body treating compositions generally intended for deodorising, protecting, adorning or grooming the body, e.g. cosmetics, dentifrices, tooth filling materials.
- Attention is drawn to the definitions of groups of chemical elements following the title of section [C](#).
- Attention is drawn to the notes in class [C07](#), for example the notes following the title of the subclass [C07D](#), setting forth the rules for classifying organic compounds in that class, which rules are also applicable, if not otherwise indicated, to the classification of organic compounds in [A61K](#).
- In this subclass, with the exception of group [A61K 8/00](#), the last place priority rule is applied, i.e. at each hierarchical level, in the absence of an indication to the contrary, classification is made in the last appropriate place.

WARNINGS

- The following IPC groups are not in the CPC scheme. The subject matter for these IPC groups is classified in the following CPC groups:

A61K 9/133	covered by	A61K 9/127
A61K 9/18	covered by	A61K 9/14
A61K 9/22	covered by	A61K 9/20
A61K 9/24	covered by	A61K 9/209
A61K 9/26	covered by	A61K 9/2077 , A61K 9/2081
A61K 9/30	covered by	A61K 9/28
A61K 9/32	covered by	A61K 9/28
A61K 9/34	covered by	A61K 9/28
A61K 9/36	covered by	A61K 9/28
A61K 9/38	covered by	A61K 9/28
A61K 9/40	covered by	A61K 9/28
A61K 9/42	covered by	A61K 9/28
A61K 9/44	covered by	A61K 9/2072
A61K 9/46	covered by	A61K 9/0007
A61K 9/52	covered by	A61K 9/50
A61K 9/54	covered by	A61K 9/5073 , A61K 9/5078 , A61K 9/5084
A61K 9/56	covered by	A61K 9/50
A61K 9/58	covered by	A61K 9/50
A61K 9/60	covered by	A61K 9/50
A61K 9/62	covered by	A61K 9/50
A61K 9/64	covered by	A61K 9/50
A61K 9/66	covered by	A61K 9/48
A61K 9/68	covered by	A61K 9/0058

A61K

A61K
(continued)

[A61K 9/72](#)
[A61K 39/108](#)
[A61K 39/112](#)
[A61K 45/08](#)
[A61K 47/04](#)
[A61K 50/00](#)

covered by
covered by
covered by
covered by
covered by
covered by

[A61K 9/0073](#)

[A61K 31/00](#), [A61K 47/00](#)
[A61K 47/02](#)
[A61K 9/0009](#), [C09J 9/02](#)

The following IPC indexing codes are not used in the CPC scheme:

[A61K 101/00](#) - [A61K 135/00](#)

2. Subgroups of [A61K 48/00](#) are incomplete (Jan. 2003). Documents are being reclassified from [A61K 48/00](#) to its subgroups
3. In this subclass non-limiting references (in the sense of paragraph 39 of the Guide to the IPC) may still be displayed in the scheme.

6/00	Preparations for dentistry (teeth cleaning preparations A61K 8/00 , A61Q 11/00 ; fastening dental prostheses in the mouth using adhesive foils or adhesive compositions { A61C 13/0025 })		
	NOTE		
	In groups A61K 6/00 - A61K 6/0044 and A61K 6/083 - A61K 6/10 , the use of specific polymers is indicated by addition of classification symbols of the subclass C08L preceded by the sign "+", e.g. compositions for taking dental impressions containing alginates are classified in A61K 6/10 + C08L 5/04		
6/0002	. {Compositions characterised by physical properties}	6/0082	. . . {comprising phosphorus-containing compounds}
6/0005	. . {by refractive index}	6/0085 {Apatite}
6/0008	. . {by particle size}	6/0088	. . . {comprising silicon-containing compounds}
6/0011	. . {by retraction, e.g. compositions for widening the sulcus for making dental impressions or removing teeth}	6/0091	. . . {Glass}
6/0014	. . {Self-expanding, e.g. for filling teeth}	6/0094	. . {Pigments}
6/0017	. . {Protective coating for natural or artificial teeth, such as sealing, dye coating, varnish}	6/0097	. . {Initiators}
6/002	. . {Compositions for detecting or measuring, e.g. contact points, irregularities on natural or artificial teeth}	6/02	. Use of preparations for artificial teeth, for filling or for capping teeth
6/0023	. {Chemical means for temporarily or permanently fixing teeth, palates or the like}	6/0205	. . {Ceramics}
6/0026	. . {Preparations for stabilising dentures in the mouth}	6/021	. . . {comprising manganese oxide}
6/0029	. {Primers (adhesive primers A61K 6/0023)}	6/0215	. . . {comprising magnesium oxide}
6/0032	. {Use of preparations for dental root treatment}	6/022	. . . {comprising beryllium oxide}
6/0035	. . {Cleaning; Disinfecting}	6/0225	. . . {comprising chromium oxide}
6/0038	. . {Filling; Sealing}	6/023	. . . {comprising iron oxide}
6/0041	. . {Apical treatment}	6/0235	. . . {comprising titanium oxide}
6/0044	. . {in combination with dental implants}	6/024	. . . {comprising zirconium oxide}
6/0047	. {Preparations for dentistry characterised by the presence of organic or organo-metallic additives}	6/0245	. . . {comprising hafnium oxide}
6/005	. . {Cationic, anionic or redox initiators}	6/025	. . . {comprising rare earth metal oxides}
6/0052	. . {Photochemical radical initiators}	6/0255	. . . {comprising transition metal oxides}
6/0055	. . {Thermal radical initiators}	6/026	. . . {Leucite}
6/0058	. . {Dyes}	6/0265	. . {Cermets-composites}
6/0061	. . . {photochromic}	6/027	. . Use of non-metallic elements or compounds thereof, e.g. carbon {(non-metallic elements per se C01B)}
6/0064	. . . {thermochromic}	6/0273	. . . {Glass-ceramic-composites}
6/0067	. . {Medicaments; Drugs}	6/0276	. . . {Glasses}
6/007	. {Preparations for dentistry characterized by the presence of inorganic additives}	6/033	. . . {Phosphorus compounds, e.g. apatite}
6/0073	. . {Fillers}	6/04	. . Use of metals or alloys (alloys per se C22C)
6/0076	. . . {comprising nitrogen-containing compounds}	6/043	. . . {Rare earth metals}
6/0079	. . . {comprising sulfur-containing compounds}	6/046	. . . {Noble metals}
		6/05	. . . Amalgams
		6/06	. . Use of inorganic cements (cements per se C04B)
		6/0606	. . . {Portland cements}
		6/0612	. . . {Silicates}
		6/0618	. . . {Pozzolans}
		6/0625	. . . {Calcium sulfates/gypsum}
		6/0631	. . . {Al-cements}
		6/0637	. . . {Ca-Al-sulfate-cements}
		6/0643	. . . {Phosphate cements (apatite A61K 6/033)}
		6/065	. . . {Ammonium cements}
		6/0656	. . . {Zeolite}
		6/0662	. . . {Quartz or SiO ₂ }
		6/0668	. . . {Carbonates}
		6/0675	. . . {Calcium oxide}
		6/0681	. . . {comprising zirconium oxide}
		6/0687	. . . {comprising chromium oxide}
		6/0693	. . . {comprising carbides}

- 6/08 . . Use of natural or synthetic resins ([resins per se C08](#))
- 6/083 . . . Compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds
- 6/0835 {Polycarboxylate cements or glass ionomer cements}
- 6/087 . . . Compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
- 6/09 Polyurethanes
- 6/093 Polyorganosilicon compounds
- 6/097 . . . Polysaccharides
- 6/10 . Compositions for taking dental impressions ([impression methods A61C 9/00](#))
- 8/00** **Cosmetics or similar toilet preparations** ([casings or accessories for storing or handling of solid or pasty toilet or cosmetic substances A45D 40/00](#))
- NOTES**
1. Use of cosmetics or similar toilet preparations is further classified in subclass [A61Q](#).
 2. Use of cosmetics or similar toilet preparations is mandatorily further classified in subclass [A61Q](#).
 3. Attention is drawn to the Notes in class [C07](#), for example the notes following the title of subclass [C07D](#), setting forth the rules for classifying organic compounds in that class, which rules are also applicable, if not otherwise indicated, to the classification of organic compounds in group [A61K 8/00](#).
 4. Salts or complexes of organic compounds are classified according to the base compounds. If a complex is formed between two or more compounds, classification is made for each compound.
- 8/02 . characterised by special physical form
- NOTE**
- In this group, the last place priority rule is applied, i.e. at each hierarchical level, in the absence of an indication to the contrary, classification is made in the last appropriate place.
- 8/0204 . . {Specific forms not provided for by any of groups [A61K 8/0208](#) - [A61K 8/14](#)}
- 8/0208 . . {Tissues; Wipes; Patches}
- 8/0212 . . {Face masks}
- 8/0216 . . {Solid or semisolid forms}
- 8/022 . . . {Powders; Compacted Powders}
- 8/0225 {Granulated powders}
- 8/0229 . . . {Sticks}
- 8/0233 . . . {Distinct layers, e.g. core/shell sticks}
- 8/0237 {Striped compositions}
- 8/0241 . . {Containing particulates characterized by their shape and/or structure ([see also A61K 8/04](#), [A61K 8/11](#), and [A61K 8/14](#), further aspects are classified in [A61K 2800/40](#) and subcodes)}
- 8/0245 . . . {Specific shapes or structures not provided for by any of the groups of [A61K 8/0241](#)}
- 8/025 . . . {Explicitly spheroidal or spherical shape}
- 8/0254 . . . {Platelets; Flakes}
- 8/0258 {Layered structure}
- 8/0262 {Characterized by the central layer}
- 8/0266 {Characterized by the sequence of layers}
- 8/027 . . . {Fibers; Fibrils}
- 8/0275 . . . {Containing agglomerated particulates}
- 8/0279 . . . {Porous; Hollow}
- 8/0283 . . . {Matrix particles}
- 8/0287 {the particulate containing a solid-in-solid dispersion}
- 8/0291 . . {Micelles}
- 8/0295 . . {Liquid crystals}
- 8/03 . . Liquid compositions with two or more distinct layers
- 8/04 . . Dispersions; Emulsions
- 8/042 . . . {Gels}
- 8/044 . . . {Suspensions}
- 8/046 . . . {Aerosols; Foams}
- 8/06 . . . Emulsions
- 8/062 {Oil-in-water emulsions}
- 8/064 {Water-in-oil emulsions, e.g. Water-in-silicone emulsions}
- 8/066 {Multiple emulsions, e.g. water-in-oil-in-water}
- 8/068 {Microemulsions}
- 8/11 . . Encapsulated compositions
- 8/14 . . Liposomes; Vesicles
- 8/18 . characterised by the composition
- NOTE**
- In this group, the last place priority rule is applied, i.e. at each hierarchical level, in the absence of an indication to the contrary, classification is made in the last appropriate place.
- 8/19 . . containing inorganic ingredients
- 8/20 . . . Halogens; Compounds thereof
- 8/21 Fluorides; Derivatives thereof
- 8/22 . . . Peroxides; Oxygen; Ozone
- 8/23 . . . Sulfur; Selenium; Tellurium; Compounds thereof
- 8/24 . . . Phosphorous; Compounds thereof
- 8/25 . . . Silicon; Compounds thereof
- 8/26 . . . Aluminium; Compounds thereof
- 8/27 . . . Zinc; Compounds thereof
- 8/28 . . . Zirconium; Compounds thereof
- 8/29 . . . Titanium; Compounds thereof
- 8/30 . . containing organic compounds
- 8/31 . . . Hydrocarbons
- 8/315 {Halogenated hydrocarbons}
- 8/33 . . . containing oxygen
- 8/34 Alcohols
- 8/342 {Alcohols having more than seven atoms in an unbroken chain}
- 8/345 {containing more than one hydroxy group}
- 8/347 {Phenols}
- 8/35 Ketones, e.g. benzophenone
- 8/355 {Quinones}
- 8/36 Carboxylic acids; Salts or anhydrides thereof
- 8/361 {Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof}
- 8/362 Polycarboxylic acids
- 8/365 Hydroxycarboxylic acids; Ketocarboxylic acids

- 8/368 with carboxyl groups directly bound to carbon atoms or aromatic rings
- 8/37 Esters of carboxylic acids
- 8/375 {the alcohol moiety containing more than one hydroxy group}
- 8/38 Percompounds, e.g. peracids
- 8/39 Derivatives containing from 2 to 10 oxyalkylene groups
- 8/40 . . . containing nitrogen ([quinones containing nitrogen A61K 8/355](#))
- 8/41 Amines
- 8/411 {Aromatic amines, i.e. where the amino group is directly linked to the aromatic nucleus}
- 8/413 {Indoanilines; Indophenol; Indoamines}
- 8/415 {Aminophenols}
- 8/416 {Quaternary ammonium compounds ([A61K 8/35 takes precedence](#))}
- 8/418 {containing nitro groups}
- 8/42 Amides
- 8/43 Guanidines
- 8/44 Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
- 8/442 {substituted by amido group(s)}
- 8/445 {aromatic, i.e. the carboxylic acid directly linked to the aromatic ring}
- 8/447 {containing sulfur}
- 8/45 Derivatives containing from 2 to 10 oxyalkylene groups
- 8/46 . . . containing sulfur ([A61K 8/44 takes precedence](#))
- 8/463 {containing sulfuric acid derivatives, e.g. sodium lauryl sulfate}
- 8/466 {containing sulfonic acid derivatives; Salts}
- 8/49 . . . containing heterocyclic compounds
- 8/4906 {with one nitrogen as the only hetero atom}
- 8/4913 {having five membered rings, e.g. pyrrolidone carboxylic acid}
- 8/492 {having condensed rings, e.g. indol}
- 8/4926 {having six membered rings}
- 8/4933 {having sulfur as an exocyclic substituent, e.g. pyridinethione}
- 8/494 {with more than one nitrogen as the only hetero atom}
- 8/4946 {Imidazoles or their condensed derivatives, e.g. benzimidazoles}
- 8/4953 {containing pyrimidine ring derivatives, e.g. minoxidil}
- 8/496 {Triazoles or their condensed derivatives, e.g. benzotriazoles}
- 8/4966 {Triazines or their condensed derivatives}
- 8/4973 {with oxygen as the only hetero atom}
- 8/498 {having 6-membered rings or their condensed derivatives, e.g. coumarin}
- 8/4986 {with sulfur as the only hetero atom}
- 8/4993 {Derivatives containing from 2 to 10 oxyalkylene groups}
- 8/55 . . . Phosphorus compounds
- 8/553 {Phospholipids, e.g. lecithin}
- 8/556 {Derivatives containing from 2 to 10 oxyalkylene groups}
- 8/58 . . . containing atoms other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur or phosphorus
- 8/585 {Organosilicon compounds}
- 8/60 . . . Sugars; Derivatives thereof
- 8/602 {Glycosides, e.g. rutin}
- 8/604 {Alkylpolyglycosides; Derivatives thereof, e.g. esters}
- 8/606 {Nucleosides; Nucleotides; Nucleic acids}
- 8/608 {Derivatives containing from 2 to 10 oxyalkylene groups}
- 8/63 . . . Steroids; Derivatives thereof
- NOTE**
- This group covers steroids, as defined in Note (1) after the title of subclass [C07J](#).
- 8/64 . . . Proteins; Peptides; Derivatives or degradation products thereof
- 8/645 {Proteins of vegetable origin; Derivatives or degradation products thereof}
- 8/65 Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
- 8/66 Enzymes
- 8/67 . . . Vitamins
- 8/671 {Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal}
- 8/673 {Vitamin B group}
- 8/675 {Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde ([tocopheryl nicotinate A61K 8/678](#))}
- 8/676 {Ascorbic acid, i.e. vitamin C}
- 8/678 {Tocopherol, i.e. vitamin E}
- 8/68 . . . Sphingolipids, e.g. ceramides, cerebroside, gangliosides
- 8/69 . . . containing fluorine
- 8/70 containing perfluoro groups, e.g. perfluoroethers
- 8/72 . . containing organic macromolecular compounds
- 8/73 . . . Polysaccharides
- 8/731 {Cellulose; Quaternized cellulose derivatives}
- 8/732 {Starch; Amylose; Amylopectin; Derivatives thereof}
- 8/733 {Alginic acid; Salts thereof}
- 8/735 {Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof}
- 8/736 {Chitin; Chitosan; Derivatives thereof}
- 8/737 {Galactomannans, e.g. guar; Derivatives thereof}
- 8/738 {Cyclodextrins}
- 8/81 . . . obtained by reactions involving only carbon-to-carbon unsaturated bonds
- 8/8105 {Compositions of homopolymers or copolymers of unsaturated aliphatic hydrocarbons having only one carbon-to-carbon double bond; Compositions of derivatives of such polymers}
- 8/8111 {Homopolymers or copolymers of aliphatic olefines, e.g. polyethylene, polyisobutene; Compositions of derivatives of such polymers}

- 8/8117 {Homopolymers or copolymers of aromatic olefines, e.g. polystyrene; Compositions of derivatives of such polymers}
- 8/8123 {Compositions of homopolymers or copolymers of compounds having one carbon-to-carbon double bond, and at least one being terminated by a halogen; Compositions of derivatives of such polymers, e.g. PVC, PTFE}
- 8/8129 {Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an alcohol, ether, aldehydo, ketonic, acetal or ketal radical; Compositions of hydrolysed polymers or esters of unsaturated alcohols with saturated carboxylic acids; Compositions of derivatives of such polymers, e.g. polyvinylmethylether}
- 8/8135 {Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an acyloxy radical of a saturated carboxylic acid, of carbonic acid or of a haloformic acid; Compositions of derivatives of such polymers, e.g. vinyl esters (polyvinylacetate)}
- 8/8141 {Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers}
- 8/8147 {Homopolymers or copolymers of acids; Metal or ammonium salts thereof, e.g. crotonic acid, (meth)acrylic acid; Compositions of derivatives of such polymers}
- 8/8152 {Homopolymers or copolymers of esters, e.g. (meth)acrylic acid esters; Compositions of derivatives of such polymers}
- 8/8158 {Homopolymers or copolymers of amides or imides, e.g. (meth) acrylamide; Compositions of derivatives of such polymers}
- 8/8164 {Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a carboxyl radical, and containing at least one other carboxyl radical in the molecule, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers, e.g. poly (methyl vinyl ether-co-maleic anhydride)}
- 8/817 {Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen; Compositions or derivatives of such polymers, e.g. vinylimidazol, vinylcaprolactame, allylamines (Polyquaternium 6)}
- 8/8176 {Homopolymers of N-vinyl-pyrrolidones. Compositions of derivatives of such polymers}
- 8/8182 {Copolymers of vinyl-pyrrolidones. Compositions of derivatives of such polymers}
- 8/8188 {Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bonds, and at least one being terminated by a bond to sulfur or by a heterocyclic ring containing sulfur; Compositions of derivatives of such polymers}
- 8/8194 {Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, at least one having two or more carbon-to-carbon double bonds; Compositions of derivatives of such polymers}
- 8/84 obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- 8/85 Polyesters
- 8/86 Polyethers
- 8/87 Polyurethanes
- 8/88 Polyamides
- 8/89 Polysiloxanes
- 8/891 saturated, e.g. dimethicone, phenyl trimethicone, C24-C28 methicone or stearyl dimethicone
- 8/892 modified by a hydroxy group, e.g. dimethiconol
- 8/893 modified by an alkoxy or aryloxy group, e.g. behenoxy dimethicone or stearoxy dimethicone
- 8/894 modified by a polyoxyalkylene group, e.g. cetyl dimethicone copolyol
- 8/895 containing silicon bound to unsaturated aliphatic groups, e.g. vinyl dimethicone
- 8/896 containing atoms other than silicon, carbon, oxygen and hydrogen, e.g. dimethicone copolyol phosphate
- 8/897 containing halogen, e.g. fluorosilicones
- 8/898 containing nitrogen, e.g. amodimethicone, trimethyl silyl amodimethicone or dimethicone propyl PG-betaine
- 8/899 containing sulfur, e.g. sodium PG-propyldimethicone thiosulfate copolyol
- 8/90 Block copolymers ([A61K 8/89 takes precedence](#))
- 8/91 Graft copolymers ([A61K 8/89 takes precedence](#))

- 8/92 . . Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- 8/922 . . . {of vegetable origin}
- 8/925 . . . {of animal origin}
- 8/927 . . . {of insects, e.g. shellac}
- 8/96 . . containing materials, or derivatives thereof of undetermined constitution
- 8/965 . . . {of inanimate origin}
- 8/97 . . . from algae, fungi, lichens or plants; from derivatives thereof

WARNING

Group [A61K 8/97](#) is impacted by reclassification into groups [A61K 8/97](#) - [A61K 8/9794](#).

All groups listed in this Warning should be considered in order to perform a complete search.

- 8/9706 Algae

WARNING

Group [A61K 8/9706](#) is incomplete pending reclassification of documents from group [A61K 8/97](#). Groups [A61K 8/9706](#) and [A61K 8/97](#) should be considered in order to perform a complete search.

Groups [A61K 8/9706](#) is also impacted by reclassification into groups [A61K 8/9706](#) - [A61K 8/9794](#). All groups listed in this Warning should be considered in order to perform a complete search

- 8/9711 Phaeophycota or Phaeophyta [brown algae], e.g. Fucus

WARNING

Group [A61K 8/9711](#) is incomplete pending reclassification of documents from groups [A61K 8/97](#) and [A61K 8/9706](#).

Groups [A61K 8/97](#), [A61K 8/9706](#) and [A61K 8/9711](#) should be considered in order to perform a complete search.

- 8/9717 Rhodophycota or Rhodophyta [red algae], e.g. Porphyra

WARNING

Group [A61K 8/9717](#) is incomplete pending reclassification of documents from groups [A61K 8/97](#) and [A61K 8/9706](#).

Groups [A61K 8/97](#), [A61K 8/9706](#) and [A61K 8/9717](#) should be considered in order to perform a complete search.

- 8/9722 Chlorophycota or Chlorophyta [green algae], e.g. Chlorella

WARNING

Group [A61K 8/9722](#) is incomplete pending reclassification of documents from groups [A61K 8/97](#) and [A61K 8/9706](#).

Groups [A61K 8/97](#), [A61K 8/9706](#) and [A61K 8/9722](#) should be considered in order to perform a complete search.

- 8/9728 Fungi, e.g. yeasts

WARNING

Group [A61K 8/9728](#) is incomplete pending reclassification of documents from groups [A61K 8/97](#) and [A61K 8/9706](#).

Groups [A61K 8/9728](#), [A61K 8/97](#) and [A61K 8/9706](#) should be considered in order to perform a complete search.

- 8/9733 Lichens

WARNING

Group [A61K 8/9733](#) is incomplete pending reclassification of documents from groups [A61K 8/97](#) and [A61K 8/9706](#).

Groups [A61K 8/9733](#) and [A61K 8/97](#) should be considered in order to perform a complete search.

- 8/9739 Bryophyta [mosses]

WARNING

Group [A61K 8/9739](#) is incomplete pending reclassification of documents from group [A61K 8/97](#).

Groups [A61K 8/9739](#), [A61K 8/97](#) and [A61K 8/9706](#) should be considered in order to perform a complete search.

- 8/9741 Pteridophyta [ferns]

WARNING

Groups [A61K 8/9741](#) and [A61K 8/9749](#) are incomplete pending reclassification of documents from groups [A61K 8/97](#) and [A61K 8/9706](#).

All the groups listed in this Warning should be considered in order to perform a complete search

- 8/9749 Filicopsida or Pteridopsida

- 8/9755 Gymnosperms [Coniferophyta]

WARNING

Groups [A61K 8/9755](#), [A61K 8/9761](#) and [A61K 8/9767](#) are incomplete pending reclassification of documents from groups [A61K 8/97](#) and [A61K 8/9706](#).

All the groups listed in this Warning should be considered in order to perform a complete search..

- 8/9761 Cupressaceae [Cypress family], e.g. juniper or cypress
 8/9767 Pinaceae [Pine family], e.g. pine or cedar
 8/9771 Ginkgoophyta, e.g. Ginkgoaceae [Ginkgo family]

WARNING

Group [A61K 8/9771](#) is incomplete pending reclassification of documents from groups [A61K 8/97](#) and [A61K 8/9706](#).

Groups [A61K 8/9771](#) and [A61K 8/97](#) should be considered in order to perform a complete search.

- 8/9778 Gnetophyta, e.g. Ephedraceae [Mormon-tea family]

WARNING

Group [A61K 8/9778](#) is incomplete pending reclassification of documents from groups [A61K 8/97](#) and [A61K 8/9706](#).

Groups [A61K 8/9778](#), [A61K 8/97](#) and [A61K 8/9706](#) should be considered in order to perform a complete search.

- 8/9783 Angiosperms [Magnoliophyta]

WARNING

Groups [A61K 8/9783](#), [A61K 8/9789](#) and [A61K 8/9794](#) are incomplete pending reclassification of documents from groups [A61K 8/97](#) and [A61K 8/9706](#).

All the groups listed in this Warning should be considered in order to perform a complete search.

- 8/9789 Magnoliopsida [dicotyledons]
 8/9794 Liliopsida [monocotyledons]
 8/98 . . . of animal origin
 8/981 {of mammals or bird}
 8/982 {Reproductive organs; Embryos, Eggs}
 8/983 {Blood, e.g. plasma}
 8/985 {Skin or skin outgrowth, e.g. hair, nails}
 8/986 {Milk; Derivatives thereof, e.g. butter}
 8/987 {of species other than mammals or birds}
 8/988 {Honey; Royal jelly, Propolis}
 8/99 . . . from microorganisms other than algae or fungi, e.g. protozoa or bacteria

WARNING

Group [A61K 8/99](#) is impacted by reclassification into groups [A61K 8/9706](#) and [A61K 8/9728](#).

All groups listed in this Warning should be considered in order to perform a complete search.

9/00

Medicinal preparations characterised by special physical form (nuclear magnetic resonance contrast preparations or magnetic resonance imaging contrast preparations [A61K 49/18](#); preparations containing radioactive substances [A61K 51/12](#))

NOTE

Among the one-dot groups of [A61K 9/00](#), classification is not made in the last appropriate place.

[A61K 9/00](#) is subdivided according to the following concepts:

- the drug release technique ([A61K 9/0002](#) and subgroups),
- the site of application ([A61K 9/0012](#) and subgroups), and
- the physical form ([A61K 9/0087](#) - [A61K 9/7023](#)).

Where relevant, documents are classified in more than one of these subdivisions.

- 9/0002 . {Galenical forms characterised by the drug release technique; Application systems commanded by energy}
 9/0004 . . {Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas}
 9/0007 . . {Effervescent ([A61K 9/0065](#) takes precedence)}
 9/0009 . . {involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis (microelectromechanical systems [A61K 9/0097](#))}
 9/0012 . {Galenical forms characterised by the site of application}
 9/0014 . . {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in [A61K 47/00](#); [A61K 9/0009](#), [A61K 9/0021](#), [A61K 9/7015](#), [A61K 9/7023](#) take precedence; cosmetic preparations [A61K 8/00](#), [A61Q](#); preparations for wound dressings or bandages [A61L 26/00](#))}
 9/0017 . . . {Non-human animal skin, e.g. pour-on, spot-on}
 9/0019 . . {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in [A61K 47/00](#))}
 9/0021 . . . {Intradermal administration, e.g. through microneedle arrays, needleless injectors (mechanical aspects [A61M](#))}
 9/0024 . . . {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration [A61K 9/0019](#); brain implants [A61K 9/0085](#); (coated) prostheses, catheters or stents [A61L](#))}
 9/0026 . . . {Blood substitute; Oxygen transporting formulations; Plasma extender}
 9/0029 . . . {Parenteral nutrition; Parenteral nutrition compositions as drug carriers}
 9/0031 . . {Rectum, anus}

- 9/0034 . . {Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants}
- 9/0036 . . . {Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms}
- 9/0039 . . . {Devices retained in the uterus for a prolonged period, e.g. intrauterine devices for contraception}
- 9/0041 . . {Mammary glands, e.g. breasts, udder; Intramammary administration}
- 9/0043 . . {Nose}
- 9/0046 . . {Ear}
- 9/0048 . . {Eye, e.g. artificial tears}
- 9/0051 . . . {Ocular inserts, ocular implants}
- 9/0053 . . {Mouth and digestive tract, i.e. intraoral and peroral administration ([rectal administration A61K 9/0031](#))}
- 9/0056 . . . {Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals}
- 9/0058 {Chewing gums ([non-medicinal aspects, preparing chewing gum A23G 4/00](#); chewing gum for care of the teeth or oral cavity, e.g. with breath freshener [A61Q 11/00](#))}
- 9/006 . . . {Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays}
- 9/0063 . . . {Periodont}
- 9/0065 . . . {Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus}
- 9/0068 . . . {Rumen, e.g. rumen bolus}
- 9/007 . . {Pulmonary tract; Aromatherapy}
- 9/0073 . . . {Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy; ([nasal sprays A61K 9/0043](#); inhalation of vapours of volatile or heated drugs, e.g. essential oils or nicotine, [A61K 9/007](#); devices [A61M](#))}
- 9/0075 {for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles}
- 9/0078 {for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions}
- 9/008 {comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]}
- 9/0082 . . . {Lung surfactant, artificial mucus}
- 9/0085 . . {Brain, e.g. brain implants; Spinal cord}
- 9/0087 . {Galenic forms not covered by [A61K 9/02](#) - [A61K 9/7023](#)}
- 9/009 . . {Sachets, pouches characterised by the material or function of the envelope ([with gastric retention A61K 9/0065](#); sachets which are not administered but function merely as a container are classified according to the content, e.g. sachets comprising powder for reconstitution of a drink [A61K 9/0095](#))}
- 9/0092 . . {Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules, nanotubes ([fibres of the matrix type containing drug A61K 9/70](#))}
- 9/0095 . . {Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches ([A61K 9/0007 takes precedence](#); eatable gels or foams [A61K 9/0056](#); oral mucosa adhesive forms [A61K 9/006](#))}
- 9/0097 . . {Micromachined devices; Microelectromechanical systems [MEMS]; Devices obtained by lithographic treatment of silicon; Devices comprising chips ([intradental microneedle arrays A61K 9/0021](#); MEMS in general [B81B 7/02](#))}
- 9/02 . . Suppositories; Bougies; Bases therefor; {Ovules} ([apparatus for making A61J 3/08](#); devices for introducing into the body [A61M 31/00](#))
- 9/025 . . {characterised by shape or structure, e.g. hollow layered, coated}
- 9/06 . . Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels ([composition of ointments, creams or gels A61K 47/00](#))}
- WARNING**
incomplete, see also [A61K 9/0012](#), [A61K 47/00](#)
- 9/08 . . Solutions {([composition of solutions A61K 47/00](#))}
- WARNING**
incomplete, see also [A61K 9/0012](#), [A61K 47/00](#), [A61K 9/0095](#)
- 9/10 . . Dispersions; Emulsions {([A61K 9/06 takes precedence](#); [composition of dispersions, emulsions A61K 47/00](#))}
- WARNING**
incomplete, see also [A61K 9/0012](#), [A61K 47/00](#), [A61K 9/0095](#)
- 9/107 . . Emulsions {; Emulsion preconcentrates; Micelles ([composition of emulsions A61K 47/00](#))}
- WARNING**
incomplete, see also [A61K 9/0012](#), [A61K 47/00](#), [A61K 9/0095](#)
- 9/1075 . . . {Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers ([A61K 9/0026 takes precedence](#))}
- 9/113 . . . Multiple emulsions, e.g. oil-in-water-in-oil {([A61K 9/0026 takes precedence](#))}
- 9/12 . . Aerosols; Foams {([A61K 9/0043](#), [A61K 9/0056](#), [A61K 9/006](#), [A61K 9/0073 take precedence](#); [spray-films A61K 9/7015](#))}
- 9/122 . . . {Foams; Dry foams ([edible foams A61K 9/0056](#))}
- 9/124 . . . {characterised by the propellant}
- 9/127 . . Liposomes
- 9/1271 . . . {Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers ([liposome as conjugate A61K 47/6911](#))}

- 9/1272 {with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids (with cholesterol as the only non-phosphatidyl surfactant [A61K 9/127](#); lipids as modifying agent [A61K 47/543](#))}
- 9/1273 {Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances (polymers grafted or coated on phosphatidyl liposomes [A61K 9/1271](#), on non-phosphatidyl liposomes [A61K 9/1272](#))}
- 9/1274 . . . {Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases}
- 9/1275 . . . {Lipoproteins; Chylomicrons; Artificial HDL, LDL, VLDL, protein-free species thereof; Precursors thereof}
- 9/1276 . . . {Globules of milk or constituents thereof}
- 9/1277 . . . {Processes for preparing; Proliposomes}
- 9/1278 {Post-loading, e.g. by ion or pH gradient}
- 9/14 . . . Particulate form, e.g. powders, {Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles (microspheres [A61K 9/16](#); microcapsules [A61K 9/50](#); nanocapsules, nanoparticles of the matrix type [A61K 9/51](#))}
- 9/141 . . {Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers ((co) spray-dried products [A61K 9/16](#), (co) lyophilised products [A61K 9/19](#); the carrier being chemically bound to the active ingredient [A61K 47/50](#))}
- 9/143 . . . {with inorganic compounds}
- 9/145 . . . {with organic compounds}
- 9/146 . . . {with organic macromolecular compounds}
- 9/148 . . . {with compounds of unknown constitution, e.g. material from plants or animals (with oils, fats, waxes, shellac [A61K 9/145](#))}
- 9/16 . . Agglomerates; Granulates; Microbeadlets {; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing, (multiple) emulsion solvent evaporation or extraction ([A61K 9/20](#) takes precedence if the final form is a tablet; microspheres with drug-free outer coating, microcapsules [A61K 9/50](#); mixture of different granules, microcapsules, (coated) microparticles [A61K 9/5084](#); nanoparticles [A61K 9/51](#))}
- 9/1605 . . . {Excipients; Inactive ingredients}
- 9/1611 {Inorganic compounds}
- 9/1617 {Organic compounds, e.g. phospholipids, fats}
- 9/1623 {Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules}
- 9/1629 {Organic macromolecular compounds}
- 9/1635 {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- 9/1641 {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers}
- 9/1647 {Polyesters, e.g. poly(lactide-co-glycolide)}
- 9/1652 {Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin (homeopathic globules [A61K 9/1623](#))}
- 9/1658 {Proteins, e.g. albumin, gelatin}
- 9/1664 {Compounds of unknown constitution, e.g. material from plants or animals (oils, fats, waxes, shellac [A61K 9/1617](#))}
- 9/167 . . . {with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface (with further drug-free outer coating [A61K 9/5073](#))}
- 9/1676 {having a drug-free core with discrete complete coating layer containing drug (adsorbates of liquid drug formulations on inert powders without simultaneous granulation step [A61K 9/141](#); with further drug-free outer coating [A61K 9/5078](#); drug conjugated to non-active particles [A61K 47/6921](#))}
- 9/1682 . . . {Processes}
- 9/1688 {resulting in pure drug agglomerate optionally containing up to 5% of excipient}
- 9/1694 {resulting in granules or microspheres of the matrix type containing more than 5% of excipient}
- 9/19 . . lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction [A61K 9/14](#); granules or pellets made by lyophilisation [A61K 9/1682](#); solid oral dosage forms made by lyophilisation [A61K 9/2095](#); lyophilisation additives [A61K 47/00](#))}
- 9/20 . . Pills, tablets, {discs, rods ([A61K 9/0004](#), [A61K 9/0007](#), [A61K 9/0056](#), [A61K 9/0065](#) take precedence; for reconstitution of a drink [A61K 9/0095](#))}
- 9/2004 . . {Excipients; Inactive ingredients}
- 9/2009 . . . {Inorganic compounds}
- 9/2013 . . . {Organic compounds, e.g. phospholipids, fats}
- 9/2018 {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- 9/2022 . . . {Organic macromolecular compounds}
- 9/2027 {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- 9/2031 {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers}
- 9/2036 {Silicones; Polysiloxanes}
- 9/204 {Polyesters, e.g. poly(lactide-co-glycolide)}
- 9/2045 {Polyamides; Polyaminoacids, e.g. polylysine}
- 9/205 {Polysaccharides, e.g. alginate, gums; Cyclodextrin}
- 9/2054 {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}

- 9/2059 {Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin}
- 9/2063 {Proteins, e.g. gelatin}
- 9/2068 . . . {Compounds of unknown constitution, e.g. material from plants or animals (oils, fats, waxes, shellac [A61K 9/2013](#))}
- 9/2072 . . {characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms ([A61K 9/0004](#), [A61K 9/0056](#), [A61K 9/0065](#) take precedence)}
- 9/2077 . . . {Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets}
- 9/2081 {with microcapsules or coated microparticles according to [A61K 9/50](#)}
- 9/2086 . . . {Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat (active cores with a complete drug-free outer coat [A61K 9/28](#))}
- 9/209 {containing drug in at least two layers or in the core and in at least one outer layer}
- 9/2095 . . {Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing (mechanical aspects [A61J 3/00](#))}
- 9/28 {Dragees; Coated pills or tablets {, e.g. with film or compression coating ([A61K 9/2072](#) takes precedence, e.g. partially coated tablets [A61K 9/2072](#), coated multilayer tablets [A61K 9/2086](#), tablets with drug-coated core [A61K 9/209](#))}
- 9/2806 . . . {Coating materials}
- 9/2813 {Inorganic compounds}
- 9/282 {Organic compounds, e.g. fats}
- 9/2826 {Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof}
- 9/2833 {Organic macromolecular compounds}
- 9/284 {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone}
- 9/2846 {Poly(meth)acrylates}
- 9/2853 {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)}
- 9/286 {Polysaccharides, e.g. gums; Cyclodextrin}
- 9/2866 {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- 9/2873 {Proteins, e.g. gelatin}
- 9/288 {Compounds of unknown constitution, e.g. material from plants or animals (oils, fats, waxes, shellac [A61K 9/282](#))}
- 9/2886 . . . {having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer (of the type active core-drug layer-inactive layer [A61K 9/209](#))}
- 9/2893 . . . {Tablet coating processes (mechanical aspects [A61J 3/06](#))}
- 9/48 . . . Preparations in capsules, e.g. of gelatin, of chocolate ([A61K 9/0004](#) takes precedence; bite capsules [A61K 9/0056](#))}
- 9/4808 . . {characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release (capsules filled with granules or microparticles [A61K 9/16](#); filled with microcapsules or coated microparticles [A61K 9/50](#); with mixture of different granules, microcapsules, (coated) microparticles [A61K 9/5084](#))}
- 9/4816 . . {Wall or shell material}
- 9/4825 . . . {Proteins, e.g. gelatin (gelatin capsule shells with substantial amounts of other macromolecular substances [A61K 9/4816](#))}
- 9/4833 . . {Encapsulating processes; Filling of capsules (mechanical aspects [A61J 3/07](#))}
- 9/4841 . . {Filling excipients; Inactive ingredients}
- 9/485 . . . {Inorganic compounds}
- 9/4858 . . . {Organic compounds}
- 9/4866 . . . {Organic macromolecular compounds}
- 9/4875 . . . {Compounds of unknown constitution, e.g. material from plants or animals (oils, fats, waxes, shellac [A61K 9/4858](#))}
- 9/4883 . . {Capsule finishing, e.g. dyeing, aromatising, polishing}
- 9/4891 . . {Coated capsules; Multilayered drug free capsule shells (with drug coating for immediate release [A61K 9/4808](#); osmotic devices [A61K 9/0004](#))}
- 9/50 . . . Microcapsules {having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals ([A61K 9/2081](#) takes precedence; particles with a single coating comprising drug [A61K 9/167](#))}
- 9/5005 . . . {Wall or coating material}
- 9/501 {Inorganic compounds}
- 9/5015 {Organic compounds, e.g. fats, sugars}
- 9/5021 {Organic macromolecular compounds}
- 9/5026 {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- 9/5031 {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)}
- 9/5036 {Polysaccharides, e.g. gums, alginate; Cyclodextrin}
- 9/5042 {Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose}
- 9/5047 {Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose}
- 9/5052 {Proteins, e.g. albumin}
- 9/5057 {Gelatin}
- 9/5063 {Compounds of unknown constitution, e.g. material from plants or animals (oils, fats, waxes, shellac [A61K 9/5015](#))}
- 9/5068 {Cell membranes or bacterial membranes enclosing drugs (with additional exogenous lipids [A61K 9/127](#); virus envelopes [A61K 9/5184](#))}

- 9/5073 . . . {having two or more different coatings optionally including drug-containing subcoatings}
- 9/5078 {with drug-free core}
- 9/5084 . . . {Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to [A61K 9/16](#) or [A61K 9/50](#), e.g. for obtaining a specific release pattern or for combining different drugs (tablets containing such a mixture [A61K 9/2077](#))}
- 9/5089 . . . {Processes}
- 9/5094 . . . {Microcapsules containing magnetic carrier material, e.g. ferrite for drug targeting}
- 9/51 . . . Nanocapsules; {Nanoparticles; (nanotubes [A61K 9/0092](#); polymeric micelles [A61K 9/1075](#); polymersomes [A61K 9/1273](#); pure drug nanoparticles [A61K 9/14](#); drug nanoparticles with adsorbed surface modifiers [A61K 9/141](#); conjugates, e.g. between drug and non-active nanoparticles, [A61K 47/50](#); preparations for in vivo diagnosis [A61K 49/00](#); with radioactive substances [A61K 51/00](#))}
- 9/5107 {Excipients; Inactive ingredients}
- 9/5115 {Inorganic compounds}
- 9/5123 {Organic compounds, e.g. fats, sugars}
- 9/513 {Organic macromolecular compounds; Dendrimers}
- 9/5138 {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- 9/5146 {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides}
- 9/5153 {Polyesters, e.g. poly(lactide-co-glycolide)}
- 9/5161 {Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin}
- 9/5169 {Proteins, e.g. albumin, gelatin}
- 9/5176 {Compounds of unknown constitution, e.g. material from plants or animals (oils, fats, waxes, shellac [A61K 9/5123](#))}
- 9/5184 {Virus capsids or envelopes enclosing drugs (with additional exogenous lipids [A61K 9/127](#); bacterial membranes [A61K 9/5068](#))}
- 9/5192 {Processes}
- 9/70 . . . Web, sheet or filament bases {; Films; Fibres of the matrix type containing drug; (hollow drug-filled fibres [A61K 9/0092](#); bandages, dressings or absorbent pads [A61F 13/00](#), chemical aspects thereof [A61L 15/00](#))}
- 9/7007 . . {Drug-containing films, membranes or sheets ([A61K 9/0041](#), [A61K 9/0043](#), [A61K 9/006](#), [A61K 9/0063](#) take precedence)}
- 9/7015 . . {Drug-containing film-forming compositions, e.g. spray-on}
- 9/7023 . . {Transdermal patches and similar drug-containing composite devices, e.g. cataplasms (galenical aspects of iontophoretic devices [A61K 9/0009](#); microneedle arrays [A61K 9/0021](#); buccal patches [A61K 9/006](#))}
- 9/703 {characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches}
- 9/7038 {Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer}
- 9/7046 {the adhesive comprising macromolecular compounds}
- 9/7053 {obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene}
- 9/7061 {Polyacrylates}
- 9/7069 {obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide}
- 9/7076 {the adhesive comprising ingredients of undetermined constitution or reaction products thereof, e.g. rosin or other plant resins}
- 9/7084 {Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches}
- 9/7092 {Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs}
- 31/00 Medicinal preparations containing organic active ingredients**
- NOTES**
- When classifying in groups [A61K 31/00](#) - [A61K 41/00](#) the symbol [A61K 2300/00](#) may be added, using Combination Sets, to indicate a mixture of active ingredients.
 - In the preparation of new organic compounds and their use in medicinal preparations, classification is only made in the relevant subclasses [C07C](#) - [C07J](#) according to the type of compound. However, the inventions dealing with medicinal preparations containing at least two active organic ingredients are always classified in this group in addition to the classification for the type of compounds in [C07C](#) - [C07J](#).
 - Attention is drawn to the notes in class [C07](#), particularly to the definition of steroids given in Note (1) following the title of [C07J](#) and to the definition of carbohydrates and sugars given in the notes following the title of [C07H](#).
 - Salts and complexes of organic active compounds are always classified according to the free active compounds. If a complex is formed between two or more active compounds, then they are classified according to all compounds forming the salts or complexes followed by the symbol [A61K 2300/00](#) (i.e. as a mixture of active organic compounds). According to the last place rule, organic active compounds forming salts with heavy metals should be classified in [A61K 33/24](#) - [A61K 33/38](#) and not in subgroups [A61K 31/28](#) - [A61K 31/32](#), [A61K 31/555](#) or [A61K 31/714](#).

A61K

A61K 31/00
(continued)

This does not apply to complexes, as apparent from the [A61K 31/00](#) scheme, wherein the complexes hemin and hematin are classified in [A61K 31/555](#) and cyanocobalamin in [A61K 31/714](#).

5. From January 2003 onwards, the EPO copies into CPC the IPC classification of the first document received (family representative). However, blends of active ingredients receive the additional symbol [A61K 2300/00](#) as Combination Set.

- 31/01 . Hydrocarbons
- 31/015 . . carbocyclic
- 31/02 . Halogenated hydrocarbons
- 31/025 . . carbocyclic
- 31/03 . . . aromatic
- 31/035 . . having aliphatic unsaturation
- 31/04 . Nitro compounds
- 31/045 . Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- 31/047 . . having two or more hydroxy groups, e.g. sorbitol
- 31/05 . . Phenols
- 31/055 . . . the aromatic ring being substituted by halogen
- 31/06 . . . the aromatic ring being substituted by nitro groups
- 31/065 . . Diphenyl-substituted acyclic alcohols
- 31/07 . . Retinol compounds, e.g. vitamin A ([retinoic acids A61K 31/203](#))
- 31/075 . Ethers or acetals
- 31/08 . . acyclic, e.g. paraformaldehyde
- 31/085 . . having an ether linkage to aromatic ring nuclear carbon
- 31/09 . . . having two or more such linkages
- 31/095 . Sulfur, selenium, or tellurium compounds, e.g. thiols
- 31/10 . . Sulfides; Sulfoxides; Sulfones
- 31/105 . . Persulfides ([thiuram disulfides A61K 31/145](#); [thiosulfonic acids A61K 31/185](#))
- 31/11 . Aldehydes
- 31/115 . . Formaldehyde
- 31/12 . Ketones
- 31/121 . . acyclic
- 31/122 . . having the oxygen directly attached to a ring, e.g. quinones, vitamin K₁, anthralin
- 31/125 . . . Camphor; Nuclear substituted derivatives thereof
- 31/13 . Amines { ([A61K 31/04 takes precedence](#)) }
- 31/131 . . acyclic
- 31/132 . . having two or more amino groups, e.g. spermidine, putrescine
- 31/133 . . having hydroxy groups, e.g. sphingosine
- 31/135 . . having aromatic rings {, e.g. [ketamine](#), [nortriptyline \(methadone A61K 31/137\)](#) }
- 31/136 . . . having the amino group directly attached to the aromatic ring, e.g. benzeneamine
- 31/137 . . . Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or [methadone](#) }
- 31/138 . . . Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine ([atenolol A61K 31/165](#); [pindolol A61K 31/404](#); [timolol A61K 31/5377](#))
- 31/14 . . Quaternary ammonium compounds, e.g. edrophonium, choline ([betaines A61K 31/205](#))


- 31/145 . . having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO₂) ([isothiurea A61K 31/155](#))
 - 31/15 . . Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N=N=) {; [Imines \(C=N=C\)](#) }
 - 31/155 . . Amidines ($\text{—N}=\overset{\text{I}}{\text{C}}\text{—N}^{\text{K}}$), e.g. guanidine (H₂N—C(=NH)—NH₂), isourea (N=C(OH)—NH₂), isothiurea (—N=C(SH)—NH₂)
 - 31/16 . Amides, e.g. hydroxamic acids
 - 31/164 . . of a carboxylic acid with an aminoalcohol, e.g. ceramides
 - 31/165 . . having aromatic rings, e.g. colchicine, atenolol, progabide
 - 31/166 . . . having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
 - 31/167 . . . having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
 - 31/17 . . having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine ([isoureas, isothiureas A61K 31/155](#); [sulfonylureas A61K 31/64](#))
 - 31/175 . . . having the group $\text{>N—C}(\text{O})\text{—}\overset{\text{I}}{\text{N}}\text{—N}^{\text{K}}$, >N—C(O)—N=N— or $\text{>N—C}(\text{O})\text{—}\overset{\text{I}}{\text{N}}\text{—N=}$, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
 - 31/18 . . Sulfonamides ([compounds containing a para-N-benzene-sulfonyl-N- group A61K 31/63](#))
 - 31/185 . Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroxamic acids ([hydroxamic acids A61K 31/16](#); [peroxy acids A61K 31/327](#))
- NOTE**
- Cyclic anhydrides are considered to be heterocyclic rings
- 31/19 . . Carboxylic acids, e.g. valproic acid ([salicylic acid A61K 31/60](#))
 - 31/191 . . . having two or more hydroxy groups, e.g. gluconic acid
 - 31/192 . . . having aromatic groups, e.g. sulindac, 2-arylpropionic acids, ethacrynic acid
 - 31/194 . . . having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
 - 31/195 . . . having an amino group
 - 31/196 the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
 - 31/197 the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid ([carnitine A61K 31/205](#))

- 31/198 Alpha-aminoacids, e.g. alanine, edetic acids [EDTA], ([betaine A61K 31/205](#); [proline A61K 31/401](#); [tryptophan A61K 31/405](#); [histidine A61K 31/4172](#); [peptides not degraded to individual aminoacids A61K 38/00](#))
- 31/20 . . . having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- 31/201 having one or two double bonds, e.g. oleic, linoleic acids
- 31/202 having three or more double bonds, e.g. linolenic ([eicosanoids, e.g. leukotrienes A61K 31/557](#))
- 31/203 Retinoic acids {[Salts thereof](#)}
- 31/205 . . Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
- 31/21 . Esters, e.g. nitroglycerine, selenocyanates
- 31/215 . . of carboxylic acids
- 31/216 . . . of acids having aromatic rings, e.g. benactizyne, clofibrate
- 31/22 . . . of acyclic acids, e.g. pravastatin
- 31/221 with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
- 31/222 with compounds having aromatic groups, e.g. dipivefrine, ibopamine
- 31/223 of alpha-aminoacids
- 31/225 Polycarboxylic acids
- 31/23 of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- 31/231 having one or two double bonds
- 31/232 having three or more double bonds, e.g. etretinate
- 31/235 . . . having an aromatic ring attached to a carboxyl group
- 31/24 having an amino or nitro group
- 31/245 Amino benzoic acid types, e.g. procaine, novocaine ([salicylic acid esters A61K 31/60](#))
- 31/25 . . . with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol
- 31/255 . . of sulfoxy acids or sulfur analogues thereof
- 31/26 . . Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
- 31/265 . . of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
- 31/27 . . of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
- 31/275 . Nitriles; Isonitriles
- 31/277 . . having a ring, e.g. verapamil
- 31/28 . Compounds containing heavy metals
- 31/282 . . Platinum compounds
- 31/285 . . Arsenic compounds
- 31/29 . . Antimony or bismuth compounds
- 31/295 . . Iron group metal compounds
- 31/30 . . Copper compounds
- 31/305 . . Mercury compounds
- 31/31 . . . containing nitrogen
- 31/315 . . Zinc compounds
- 31/32 . . Tin compounds
- 31/325 . Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof ([thiurams A61K 31/145](#))
- 31/327 . Peroxy compounds, e.g. hydroperoxides, peroxides, peroxyacids
- 31/33 . Heterocyclic compounds
- 31/335 . . having oxygen as the only ring hetero atom, e.g. fungichromin
- 31/336 . . . having three-membered rings, e.g. oxirane, fumagillin
- 31/337 . . . having four-membered rings, e.g. taxol
- 31/34 . . . having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- 31/341 not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
- 31/343 condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- 31/345 Nitrofurans ([nitrofurantoin A61K 31/4178](#))
- 31/35 . . . having six-membered rings with one oxygen as the only ring hetero atom
- 31/351 not condensed with another ring
- 31/352 condensed with carbocyclic rings, e.g. cannabinoids, methanheline
- 31/353 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- 31/355 Tocopherols, e.g. vitamin E
- 31/357 . . . having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- 31/36 Compounds containing methylenedioxyphenyl groups, e.g. sesamin
- 31/365 . . . Lactones
- 31/366 having six-membered rings, e.g. delta-lactones
- 31/37 Coumarins, e.g. psoralen
- 31/375 Ascorbic acid, i.e. vitamin C; Salts thereof
- 31/38 . . having sulfur as a ring hetero atom
- 31/381 . . . having five-membered rings
- 31/382 . . . having six-membered rings, e.g. thioxanthenes ([thiotixene A61K 31/496](#))
- 31/385 . . . having two or more sulfur atoms in the same ring
- 31/39 . . . having oxygen in the same ring
- 31/395 . . having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins ([rifampin A61K 31/496](#))
- WARNING**
- Group [A61K 31/395](#) is impacted by reclassification into group [A61K 31/5545](#). Groups [A61K 31/395](#) and [A61K 31/5545](#) should be considered in order to perform a complete search.
- 31/396 . . . having three-membered rings, e.g. aziridine
- 31/397 . . . having four-membered rings, e.g. azetidine
- 31/40 . . . having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulphiride, succinimide, tolmetin, buflomedil
- 31/401 Proline; Derivatives thereof, e.g. captopril
- 31/4015 having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
- 31/402 1-aryl substituted, e.g. piretanide
- 31/4025 not condensed and containing further heterocyclic rings, e.g. cromakalim

- 31/403 condensed with carbocyclic rings, e.g. carbazole
- 31/4035 Isoindoles, e.g. phthalimide
- 31/404 Indoles, e.g. pindolol
- 31/4045 Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- 31/405 Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- 31/407 condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- 31/409 having four such rings, e.g. porphine derivatives, bilirubin, biliverdine ([hemin](#), [hemin A61K 31/555](#))
- 31/41 having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- 31/415 1,2-Diazoles
- 31/4152 having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
- 31/4155 non condensed and containing further heterocyclic rings
- 31/416 condensed with carbocyclic ring systems, e.g. indazole
- 31/4162 condensed with heterocyclic ring systems
- 31/4164 1,3-Diazoles
- 31/4166 having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
- 31/4168 having a nitrogen attached in position 2, e.g. clonidine
- 31/417 Imidazole-alkylamines, e.g. histamine, phentolamine
- 31/4172 Imidazole-alkanecarboxylic acids, e.g. histidine
- 31/4174 Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
- 31/4178 not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- 31/4184 condensed with carbocyclic rings, e.g. benzimidazoles
- 31/4188 condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
- 31/4192 1,2,3-Triazoles
- 31/4196 1,2,4-Triazoles
- 31/42 Oxazoles
- 31/421 1,3-Oxazoles, e.g. pemoline, trimethadione
- 31/422 not condensed and containing further heterocyclic rings
- 31/423 condensed with carbocyclic rings
- 31/424 condensed with heterocyclic ring systems, e.g. clavulanic acid
- 31/4245 Oxadiazoles
- 31/425 Thiazoles
- 31/426 1,3-Thiazoles
- 31/427 not condensed and containing further heterocyclic rings
- 31/428 condensed with carbocyclic rings
- 31/429 condensed with heterocyclic ring systems
- 31/43 Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula  , e.g. penicillins, penems
- 31/431 containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
- 31/433 Thiadiazoles
- 31/435 having six-membered rings with one nitrogen as the only ring hetero atom
- 31/4353 ortho- or peri-condensed with heterocyclic ring systems
- 31/4355 the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
- 31/436 the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- 31/4365 the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
- 31/437 the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- 31/4375 the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
- 31/438 the ring being spiro-condensed with carbocyclic ring systems
- 31/439 the ring forming part of a bridged ring system, e.g. quinuclidine ([8-azabicyclo \[3.2.1\] octanes A61K 31/46](#))
- 31/44 Non condensed pyridines; Hydrogenated derivatives thereof
- 31/4402 only substituted in position 2, e.g. pheniramine, bisacodyl
- 31/4406 only substituted in position 3, e.g. zimeldine ([nicotinic acid A61K 31/455](#))
- 31/4409 only substituted in position 4, e.g. isoniazid, iproniazid
- 31/4412 having oxo groups directly attached to the heterocyclic ring
- 31/4415 Pyridoxine, i.e. Vitamin B₆ ([pyridoxal phosphate A61K 31/675](#))
- 31/4418 having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
- 31/4422 1,4-Dihydropyridines, e.g. nifedipine, nicardipine
- 31/4425 Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
- 31/4427 containing further heterocyclic ring systems
- 31/443 containing a five-membered ring with oxygen as a ring hetero atom
- 31/4433 containing a six-membered ring with oxygen as a ring hetero atom
- 31/4436 containing a heterocyclic ring having sulfur as a ring hetero atom

31/4439	containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K 31/465)	31/4741	condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
31/444	containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone	31/4743	condensed with ring systems having sulfur as a ring hetero atom
31/445	Non condensed piperidines, e.g. piperocaine	31/4745	condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives , vinblastine A61K 31/475 ; ergoline derivatives A61K 31/48)
31/4453	only substituted in position 1, e.g. propipocaine, diperodon	31/4747	spiro-condensed
31/4458	only substituted in position 2, e.g. methylphenidate	31/4748	forming part of bridged ring systems (strychnine A61K 31/475 ; morphinan derivatives A61K 31/485)
31/4462	only substituted in position 3	31/475	having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine (vincamine A61K 31/4375)
31/4465	only substituted in position 4	31/48	Ergoline derivatives, e.g. lysergic acid, ergotamine
31/4468	having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl	31/485	Morphinan derivatives, e.g. morphine, codeine
31/45	having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide	31/49	Cinchonan derivatives, e.g. quinine
31/451	having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, pimindine	31/495	. . .	having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines } (A61K 31/48 takes precedence ; with three nitrogen atoms A61K 31/53)
31/4515	having a butyrophenone group in position 1, e.g. haloperidol (pipamperone A61K 31/4545)	31/496	Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
31/452	Piperidinium derivatives (pancuronium A61K 31/58)	31/4965	Non-condensed pyrazines
31/4523	containing further heterocyclic ring systems	31/497	containing further heterocyclic rings
31/4525	containing a five-membered ring with oxygen as a ring hetero atom	31/498	Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
31/453	containing a six-membered ring with oxygen as a ring hetero atom	31/4985	Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
31/4535	containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen	31/499	Spiro-condensed pyrazines or piperazines
31/454	containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozone, domperidone	31/4995	Pyrazines or piperazines forming part of bridged ring systems
31/4545	containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine	31/50	Pyridazines; Hydrogenated pyridazines
31/455	Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides	31/501	not condensed and containing further heterocyclic rings
31/46	8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine	31/502	ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
31/465	Nicotine; Derivatives thereof	31/5025	ortho- or peri-condensed with heterocyclic ring systems
31/47	Quinolines; Isoquinolines	31/503	spiro-condensed
31/4704	2-Quinolines, e.g. carbostyryl	31/504	forming part of bridged ring systems
31/4706	4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine	31/505	Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
31/4709	Non-condensed quinolines and containing further heterocyclic rings	31/506	not condensed and containing further heterocyclic rings
31/472	Non-condensed isoquinolines, e.g. papaverine	31/51	Thiamines, e.g. vitamin B ₁
31/4725	containing further heterocyclic rings	31/513	having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
31/473	ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines	31/515	Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
31/4738	ortho- or peri-condensed with heterocyclic ring systems	31/517	ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
			31/519	ortho- or peri-condensed with heterocyclic rings
			31/52	Purines, e.g. adenine

- 31/522 having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- 31/525 Isoalloxazines, e.g. riboflavins, vitamin B₂
- 31/527 spiro-condensed
- 31/529 forming part of bridged ring systems
- 31/53 . . . having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazaniol, melamine ([melarsoprol A61K 31/555](#) ; with four nitrogen atoms [A61K 31/495](#))
- 31/535 . . . having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- 31/5355 Non-condensed oxazines and containing further heterocyclic rings
- 31/536 ortho- or peri-condensed with carbocyclic ring systems
- 31/5365 ortho- or peri-condensed with heterocyclic ring systems
- 31/537 spiro-condensed or forming part of bridged ring systems
- 31/5375 1,4-Oxazines, e.g. morpholine
- 31/5377 not condensed and containing further heterocyclic rings, e.g. timolol
- 31/538 ortho- or peri-condensed with carbocyclic ring systems
- 31/5383 ortho- or peri-condensed with heterocyclic ring systems
- 31/5386 spiro-condensed or forming part of bridged ring systems
- 31/539 having two or more oxygen atoms in the same ring, e.g. dioxazines
- 31/5395 having two or more nitrogen atoms in the same ring, e.g. oxadiazines
- 31/54 . . . having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- 31/541 Non-condensed thiazines containing further heterocyclic rings
- 31/5415 ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
- 31/542 ortho- or peri-condensed with heterocyclic ring systems
- 31/545 Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:



cephalosporins, {[cefaclor](#), or [cephalexine](#)}

- 31/546 containing further heterocyclic rings, e.g. cephalothin
- 31/547 spiro-condensed or forming part of bridged ring systems
- 31/548 having two or more sulfur atoms in the same ring
- 31/549 having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
- 31/55 . . . having seven-membered rings, e.g. azelastine, pentylene-tetrazole
- 31/551 having two nitrogen atoms, e.g. dilazep

- 31/5513 1,4-Benzodiazepines, e.g. diazepam {or [clozapine](#)}
- 31/5517 condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
- 31/553 having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
- 31/554 having at least one nitrogen and one sulfur as ring hetero atoms, e.g. chlothiapine, diltiazem
- 31/5545 . . . {[having eight-membered rings not containing additional condensed or non-condensed nitrogen-containing 3-7 membered rings](#)}

NOTE

This subgroup [does not cover](#) N-containing eight-membered rings which also contain additional condensed and non-condensed nitrogen containing 3-7 membered rings, which are covered by subgroups [A61K 31/396](#) - [A61K 31/554](#).

WARNING

Group [A61K 31/5545](#) is incomplete pending reclassification of documents from group [A61K 31/395](#).

Groups [A61K 31/395](#) and [A61K 31/5545](#) should be considered in order to perform a complete search.

- 31/555 . . . containing heavy metals, e.g. hemin, hematin, melarsoprol
- 31/557 . . . Eicosanoids, e.g. leukotrienes {or [prostaglandins](#)}
- 31/5575 . . . having a cyclopentane, e.g. prostaglandin E₂, prostaglandin F_{2-α}
- 31/5578 . . . having a pentalene ring system, e.g. carbacyclin, iloprost
- 31/558 . . . having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
- 31/5585 . . . having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
- 31/559 . . . having heterocyclic rings containing hetero atoms other than oxygen
- 31/56 . . . Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids

NOTE

Attention is drawn to Note (1) following the title of subclass [C07J](#) which explains what is covered by the term "steroids"

- 31/565 . . . not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- 31/566 . . . having an oxo group in position 17, e.g. estrone
- 31/567 . . . substituted in position 17 alpha, e.g. mestranol, norethandrolone
- 31/568 . . . substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- 31/5685 having an oxo group in position 17, e.g. androsterone
- 31/569 substituted in position 17 alpha, e.g. ethisterone

- 31/57 . . substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
- 31/573 . . . substituted in position 21, e.g. cortisone, dexamethasone, prednisone {or aldosterone}
- 31/575 . . substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
- 31/58 . . containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin {(digitoxin A61K 31/7048)}
- 31/585 . . . containing lactone rings, e.g. oxandrolone, bufalin
- 31/59 . Compounds containing 9, 10- seco-cyclopenta[a]hydrophenanthrene ring systems
- 31/592 . . 9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D₂
- 31/593 . . 9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D₃
- 31/60 . Salicylic acid; Derivatives thereof
- 31/603 . . having further aromatic rings, e.g. diflunisal
- 31/606 . . having amino groups
- 31/609 . . Amides, e.g. salicylamide {(labetalol, metoclopramide A61K 31/166)}
- 31/612 . . having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid (fosfosal A61K 31/661)
- 31/616 . . . by carboxylic acids, e.g. acetylsalicylic acid
- 31/618 . . having the carboxyl group in position 1 esterified, e.g. salsalate
- 31/621 . . . having the hydroxy group in position 2 esterified, e.g. benorylate
- 31/625 . . having heterocyclic substituents, e.g. 4-salicylcloylmorpholine, (sulfasalazine A61K 31/635)
- 31/63 . Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- 31/635 . . having a heterocyclic ring, e.g. sulfasalazine
- 31/64 . Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
- 31/65 . Tetracyclines
- 31/655 . Azo (—N=N—), diazo (=N_2), azoxy (>N—O—N< or N(=O)—N<), azido (—N_3) or diazoamino (—N=N—N<) compounds
- 31/66 . Phosphorus compounds
- 31/661 . . Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion {or mevinphos}
- 31/6615 . . . Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
- 31/662 . . Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- 31/663 . . . Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
- 31/664 . . Amides of phosphorus acids
- 31/665 . . having oxygen as a ring hetero atom, e.g. fosfomycin
- 31/67 . . having sulfur as a ring hetero atom
- 31/675 . . having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- 31/683 . . Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- 31/685 . . . one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
- 31/688 . . . both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
- 31/69 . Boron compounds
- 31/695 . Silicon compounds
- 31/70 . Carbohydrates; Sugars; Derivatives thereof (sorbitol A61K 31/047)
- NOTE**
- In this group, the expressions are used with the meanings indicated in Note (3) following the title of the subclass C07H
- 31/7004 . . Monosaccharides having only carbon, hydrogen and oxygen atoms
- 31/7008 . . Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
- 31/7012 . . Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid (gluconic acid A61K 31/191; ascorbic acid A61K 31/375)
- 31/7016 . . Disaccharides, e.g. lactose, lactulose (lactobionic acid A61K 31/7032)
- 31/702 . . Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
- 31/7024 . . Esters of saccharides
- 31/7028 . . Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- 31/7032 . . . attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
- 31/7034 . . . attached to a carbocyclic compound, e.g. phloridzin
- 31/7036 having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
- 31/704 attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K 31/7048)}
- 31/7042 . . Compounds having saccharide radicals and heterocyclic rings
- 31/7048 . . . having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {digitoxin or digoxin}
- 31/7052 . . . having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- 31/7056 containing five-membered rings with nitrogen as a ring hetero atom
- 31/706 containing six-membered rings with nitrogen as a ring hetero atom
- 31/7064 containing condensed or non-condensed pyrimidines
- 31/7068 having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid

- 31/7072 having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
- 31/7076 containing purines, e.g. adenosine, adenylic acid
- 31/708 having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
- 31/7084 . . Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
- 31/7088 . . Compounds having three or more nucleosides or nucleotides
- 31/7105 . . . Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- 31/711 . . . Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
- 31/7115 . . . Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
- 31/712 . . . Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
- 31/7125 . . . Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiester
- 31/713 . . . Double-stranded nucleic acids or oligonucleotides
- 31/7135 . . Compounds containing heavy metals
- 31/714 . . . Cobalamins, e.g. cyanocobalamin, i.e. vitamin B₁₂
- 31/715 . . Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- 31/716 . . . Glucans
- 31/717 . . . Celluloses
- 31/718 . . . Starch or degraded starch, e.g. amylose, amylopectin
- 31/719 . . . Pullulans
- 31/721 . . . Dextrans
- 31/722 . . . Chitin, chitosan
- 31/723 . . . Xanthans
- 31/724 . . . Cyclodextrins
- 31/726 . . . Glycosaminoglycans, i.e. mucopolysaccharides (chondroitin sulfate, dermatan sulfate [A61K 31/737](#))
- 31/727 . . . Heparin; Heparan
- 31/728 . . . Hyaluronic acid
- 31/729 . . . Agar; Agarose; Agaropectin
- 31/731 . . . Carrageenans
- 31/732 . . . Pectin
- 31/733 . . . Fructosans, e.g. inulin
- 31/734 . . . Alginic acid
- 31/736 . . . Glucomannans or galactomannans, e.g. locust bean gum, guar gum
- 31/737 . . . Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate ([A61K 31/727](#) takes precedence)
- 31/738 . . . Cross-linked polysaccharides
- 31/739 . . . Lipopolysaccharides
- 31/74 . . Synthetic polymeric materials
- 31/745 . . Polymers of hydrocarbons
- 31/75 . . . of ethene
- 31/755 . . Polymers containing halogen
- 31/76 . . . of vinyl chloride
- 31/765 . . Polymers containing oxygen
- 31/77 . . . of oxiranes
- 31/775 . . . Phenolic resins
- 31/78 . . . of acrylic acid or derivatives thereof
- 31/785 . . Polymers containing nitrogen
- 31/787 . . . containing heterocyclic rings having nitrogen as a ring hetero atom
- 31/79 Polymers of vinyl pyrrolidone
- 31/795 . . Polymers containing sulfur
- 31/80 . . Polymers containing hetero atoms not provided for in groups [A61K 31/755](#) - [A61K 31/795](#)
- 33/00 Medicinal preparations containing inorganic active ingredients**
- 33/02 . Ammonia; Compounds thereof
- 33/04 . Sulfur, selenium or tellurium; Compounds thereof
- 33/06 . Aluminium, calcium or magnesium; Compounds thereof {, e.g. clay}
- 33/08 . Oxides; Hydroxides
- 33/10 . Carbonates; Bicarbonates
- 33/12 . Magnesium silicate
- 33/14 . Alkali metal chlorides; Alkaline earth metal chlorides
- 33/16 . Fluorine compounds
- 33/18 . Iodine; Compounds thereof
- 33/20 . Elemental chlorine; Inorganic compounds releasing chlorine
- 33/22 . Boron compounds
- 33/24 . Heavy metals; Compounds thereof
- WARNING**
- Group [A61K 33/24](#) is impacted by reclassification into groups [A61K 33/241](#), [A61K 33/242](#), [A61K 33/243](#), [A61K 33/244](#) and [A61K 51/00](#) - [A61K 51/1296](#).
- All groups listed in this Warning should be considered in order to perform a complete search.
- 33/241 . . Lead; Compounds thereof
- WARNING**
- Group [A61K 33/241](#) is incomplete pending reclassification of documents from group [A61K 33/24](#).
- Groups [A61K 33/24](#) and [A61K 33/241](#) should be considered in order to perform a complete search.
- 33/242 . . Gold; Compounds thereof
- WARNING**
- Group [A61K 33/242](#) is incomplete pending reclassification of documents from group [A61K 33/24](#).
- Groups [A61K 33/24](#) and [A61K 33/242](#) should be considered in order to perform a complete search.

33/243	. . Platinum; Compounds thereof	35/12	. Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells (uncharacterised stem cells A61K 35/545 ; vaccines or medicinal preparations containing antigens or antibodies A61K 39/00)
	<u>WARNING</u>		<u>NOTE</u>
	Group A61K 33/243 is incomplete pending reclassification of documents from group A61K 33/24 .		If the cells are characterised, classification is made in the group covering the corresponding tissue or tissue of origin.
	Groups A61K 33/24 and A61K 33/243 should be considered in order to perform a complete search.		
33/244	. . Lanthanides; Compounds thereof (medicinal preparations containing radioactive lanthanides for use in therapy or testing in vivo A61K 51/00)	2035/122	. . {for inducing tolerance or suppression of immune responses}
	<u>WARNING</u>	2035/124	. . {the cells being hematopoietic, bone marrow derived or blood cells}
	Group A61K 33/244 is incomplete pending reclassification of documents from group A61K 33/24 .	2035/126	. . {Immunoprotecting barriers, e.g. jackets, diffusion chambers}
	Groups A61K 33/24 and A61K 33/244 should be considered in order to perform a complete search.	2035/128	. . . {capsules, e.g. microcapsules}
33/245	. . Bismuth; Compounds thereof	35/13	. . Tumour cells, irrespective of tissue of origin (tumour vaccines A61K 39/00)
33/26	. . Iron; Compounds thereof	35/14	. . Blood; Artificial blood (perfluorocarbons A61K 31/02 ; umbilical cord blood A61K 35/51 ; haemoglobin A61K 38/42)
33/28	. . Mercury; Compounds thereof	35/15	. . . Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells (presenting a specific antigen A61K 39/00 ; therapeutic combinations of antibodies, or fragments thereof, and blood-derived cells A61K 39/00)
33/30	. . Zinc; Compounds thereof	35/16	. . . Blood plasma; Blood serum (umbilical cord blood A61K 35/51)
33/32	. . Manganese; Compounds thereof	35/17	. . . Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K 39/00)
33/34	. . Copper; Compounds thereof	35/18	. . . Erythrocytes (haemoglobin A61K 38/42)
33/36	. . Arsenic; Compounds thereof	35/19	. . . Platelets; Megacaryocytes
33/38	. . Silver; Compounds thereof	35/20	. . Milk; Whey; Colostrum
33/40	. Peroxides	35/22	. . Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
33/42	. Phosphorus; Compounds thereof	35/24	. . Mucus; Mucous glands; Bursa; Synovial fluid; Arthral fluid; Excreta; Spinal fluid (saliva A61K 35/38)
33/44	. Elemental carbon, e.g. charcoal, carbon black	35/26	. . Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
35/00	Medicinal preparations containing materials or reaction products thereof with undetermined constitution	35/28	. . Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
	<u>NOTES</u>	35/30	. . Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
	1. In this group, classification is made for each active component or material. For each active component or material, classification is then made in the last appropriate place.	35/32	. . Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
	2. When classifying in this group, classification is also made in group B01D 15/08 insofar as subject matter of general interest relating to chromatography is concerned.	35/33	. . Fibroblasts
35/02	. from inanimate materials (carbon A61K 33/44)	35/34	. . Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes (vascular smooth muscle A61K 35/44)
35/04	. . Tars; Bitumens; Mineral oils; Ammonium bituminosulfonate		
35/06	. . . Mineral oils, e.g. paraffinic oils or aromatic oils based on aromatic hydrocarbons		
35/08	. . Mineral waters; Sea water		
35/10	. . Peat; Amber; Turf; Humus		
2035/11	. . { Medicinal preparations comprising living procariotic cells }		
2035/115	. . { Probiotics }		

- 35/35 . . Fat tissue; Adipocytes; Stromal cells; Connective tissues ([adipose-derived stem cells A61K 35/28](#); [collagen A61K 38/39](#))
- 35/36 . . Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells ([islets of Langerhans A61K 35/39](#))
- 35/37 . . Digestive system
- 35/38 . . . Stomach; Intestine; Goblet cells; Oral mucosa; Saliva
- 35/39 . . . Pancreas; Islets of Langerhans ([Langerhans cells of epidermis A61K 35/36](#))
- 35/407 . . . Liver; Hepatocytes
- 35/413 . . . Gall bladder; Bile
- 35/42 . . Respiratory system, e.g. lungs, bronchi or lung cells
- 35/44 . . Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
- 35/48 . . Reproductive organs
- 35/50 . . . Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
- 35/51 . . . Umbilical cord; Umbilical cord blood; Umbilical stem cells
- 35/52 . . . Sperm; Prostate; Seminal fluid; Leydig cells of testes
- 35/54 . . . Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
- 35/545 Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
- 35/55 . . Glands not provided for in groups [A61K 35/22](#) - [A61K 35/545](#), e.g. thyroids, parathyroids or pineal glands
- 35/56 . . Materials from animals other than mammals
- 35/57 . . Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
- 35/58 . . Reptiles ([antigens from snakes A61K 39/38](#))
- 35/583 . . . Snakes; Lizards, e.g. chameleons ([therapeutic use of a snake venom protein A61K 38/00](#))
- 35/586 . . . Turtles; Tortoises, e.g. terrapins
- 35/60 . . Fish, e.g. seahorses; Fish eggs
- 35/612 . . Crustaceans, e.g. crabs, lobsters, shrimps, krill or crayfish; Barnacles
- 35/614 . . Cnidaria, e.g. sea anemones, corals, coral animals or jellyfish
- 35/616 . . Echinodermata, e.g. starfish, sea cucumbers or sea urchins
- 35/618 . . Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
- 35/62 . . Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
- 35/63 . . Arthropods ([aquatic crustaceans A61K 35/612](#))
- 35/64 . . . Insects, e.g. bees, wasps or fleas
- 35/644 Beeswax; Propolis; Royal jelly; Honey
- 35/646 . . . Arachnids, e.g. spiders, scorpions, ticks or mites
- 35/648 . . . Myriapods, e.g. centipedes or millipedes
- 35/65 . . Amphibians, e.g. toads, frogs, salamanders or newts
- 35/655 . . Aquatic animals other than those covered by groups [A61K 35/57](#) - [A61K 35/65](#)
- 35/66 . . Microorganisms or materials therefrom ([fungi, yeasts or candida A61K 36/06](#))
- 35/68 . . Protozoa, e.g. flagella, amoebas, sporozoans, plasmodium or toxoplasma
- 35/74 . . Bacteria ([therapeutic use of a bacterial protein A61K 38/00](#))
- 35/741 . . . Probiotics ([probiotic yeast, e.g. saccharomyces A61K 36/06](#))
- 35/742 Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
- 35/744 Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- 35/745 Bifidobacteria
- 35/747 Lactobacilli, e.g. L. acidophilus or L. brevis
- 35/748 . . . Cyanobacteria, i.e. blue-green bacteria or blue-green algae, e.g. spirulina ([algae, microalgae or microphytes A61K 36/02](#))
- 35/76 . . Viruses; Subviral particles; Bacteriophages
- 35/761 . . . Adenovirus
- 35/763 . . . Herpes virus
- 35/765 . . . Reovirus; Rotavirus
- 35/766 . . . Rhabdovirus, e.g. vesicular stomatitis virus
- 35/768 . . . Oncolytic viruses not provided for in groups [A61K 35/761](#) - [A61K 35/766](#)
- 36/00 Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines {(antigens from pollen A61K 39/36)}**
- NOTE**
- In this group, common names of plants, where given, are presented in brackets following their corresponding Latin names.
- 36/02 . . Algae
- 36/03 . . Phaeophycota or phaeophyta (brown algae), e.g. Fucus
- 36/04 . . Rhodophycota or rhodophyta (red algae), e.g. Porphyra
- 36/05 . . Chlorophycota or chlorophyta (green algae), e.g. Chlorella
- 36/06 . . Fungi, e.g. yeasts
- 36/062 . . Ascomycota
- 36/064 . . . Saccharomycetales, e.g. baker's yeast
- 36/066 . . . Clavicipitaceae
- 36/068 Cordyceps
- 36/07 . . Basidiomycota, e.g. Cryptococcus
- 36/074 . . . Ganoderma
- 36/076 . . . Poria
- 36/09 . . Lichens
- 36/10 . . Bryophyta
- 36/11 . . Pteridophyta or Filicophyta (ferns)
- 36/12 . . Filicopsida or Pteridopsida
- 36/126 . . . Drynaria
- 36/13 . . Coniferophyta (gymnosperms)
- 36/14 . . Cupressaceae (Cypress family), e.g. juniper or cypress
- 36/15 . . Pinaceae (Pine family), e.g. pine or cedar
- 36/16 . . Ginkgoophyta, e.g. Ginkgoaceae (Ginkgo family)

36/17	. Gnetophyta, e.g. Ephedraceae (Mormon-tea family)	36/37	. . . Celastraceae (Staff-tree or Bittersweet family), e.g. tripterygium or spindletree
36/18	. Magnoliophyta (angiosperms)	36/38	. . . Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
36/185	. . Magnoliopsida (dicotyledons)	36/39	. . . Convolvulaceae (Morning-glory family), e.g. bindweed
36/19	. . . Acanthaceae (Acanthus family)	36/40	. . . Cornaceae (Dogwood family)
36/195 Strobilanthes	36/41	. . . Crassulaceae (Stonecrop family)
36/20	. . . Aceraceae (Maple family)	36/42	. . . Cucurbitaceae (Cucumber family)
36/21 Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth	36/424 Gynostemma
36/22	. . . Anacardiaceae (Sumac family), e.g. smoketree, sumac or poison oak	36/428 Trichosanthes
36/23	. . . Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin	36/43	. . . Cuscutaceae (Dodder family), e.g. Cuscuta epithymum or greater dodder
36/232 Angelica	36/44	. . . Ebenaceae (Ebony family), e.g. persimmon
36/233 Bupleurum	36/45	. . . Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
36/234 Cnidium (snowparsley)	36/46	. . . Eucommiaceae (Eucommia family), e.g. hardy rubber tree
36/235 Foeniculum (fennel)	36/47	. . . Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
36/236 Ligusticum (licorice-root)	36/48	. . . Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
36/237 Notopterygium	36/481 Astragalus (milkvetch)
36/238 Saposhnikovia	36/482 Cassia, e.g. golden shower tree
36/24	. . . Apocynaceae (Dogbane family), e.g. plumeria or periwinkle	36/483 Gleditsia (locust)
36/25	. . . Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax	36/484 Glycyrrhiza (licorice)
36/254 Acanthopanax or Eleutherococcus	36/485 Gueldenstaedtia
36/258 Panax (ginseng)	36/486 Millettia
36/26	. . . Aristolochiaceae (Birthwort family), e.g. heartleaf	36/487 Psoralea
36/264 Aristolochia (Dutchman's pipe)	36/488 Pueraria (kudzu)
36/268 Asarum (wild ginger)	36/489 Sophora, e.g. necklacepod or mamani
36/27	. . . Asclepiadaceae (Milkweed family), e.g. hoyia	36/49	. . . Fagaceae (Beech family), e.g. oak or chestnut
36/28	. . . Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea	36/50	. . . Fumariaceae (Fumitory family), e.g. bleeding heart
36/282 Artemisia, e.g. wormwood or sagebrush	36/505 Corydalis
36/284 Atractylodes	36/51	. . . Gentianaceae (Gentian family)
36/285 Aucklandia	36/515 Gentiana
36/286 Carthamus (distaff thistle)	36/52	. . . Juglandaceae (Walnut family)
36/287 Chrysanthemum, e.g. daisy	36/53	. . . Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
36/288 Taraxacum (dandelion)	36/532 Agastache, e.g. giant hyssop
36/289 Vladimiria	36/533 Leonurus (motherwort)
36/29	. . . Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple	36/534 Mentha (mint)
36/296 Epimedium	36/535 Perilla (beefsteak plant)
36/30	. . . Boraginaceae (Borage family), e.g. comfrey, lungwort or forget-me-not	36/536 Prunella or Brunella (selfheal)
36/31	. . . Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi	36/537 Salvia (sage)
36/315 Isatis, e.g. Dyer's woad	36/538 Schizonepeta
36/32	. . . Burseraceae (Frankincense family)	36/539 Scutellaria (skullcap)
36/324 Boswellia, e.g. frankincense	36/54	. . . Lauraceae (Laurel family), e.g. cinnamon or saffrafrs
36/328 Commiphora, e.g. mecca myrrh or balm of Gilead	36/55	. . . Linaceae (Flax family), e.g. Linum
36/33	. . . Cactaceae (Cactus family), e.g. pricklypear or Cereus	36/56	. . . Loganiaceae (Logania family), e.g. trumpetflower or pinkroot
36/34	. . . Campanulaceae (Bellflower family)	36/57	. . . Magnoliaceae (Magnolia family)
36/342 Adenophora	36/575 Magnolia
36/344 Codonopsis	36/58	. . . Meliaceae (Chinaberry or Mahogany family), e.g. Azadirachta (neem)
36/346 Platycodon	36/59	. . . Menispermaceae (Moonseed family), e.g. hyperbaena or coralbead
36/35	. . . Caprifoliaceae (Honeysuckle family)	36/60	. . . Moraceae (Mulberry family), e.g. breadfruit or fig
36/355 Lonicera (honeysuckle)		
36/36	. . . Caryophyllaceae (Pink family), e.g. babysbreath or soapwort		

36/605 Morus (mulberry)	36/84 Valerianaceae (Valerian family), e.g. valerian
36/61 Myrtaceae (Myrtle family), e.g. teatree or eucalyptus	36/85 Verbenaceae (Verbena family)
36/62 Nymphaeaceae (Water-lily family)	36/855 Clerodendrum, e.g. glorybower
36/63 Oleaceae (Olive family), e.g. jasmine, lilac or ash tree	36/86 Violaceae (Violet family)
36/634 Forsythia	36/87 Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
36/638 Ligustrum, e.g. Chinese privet	36/88 Liliopsida (monocotyledons)
36/64 Orobanchaceae (Broom-rape family)	36/882 Acoraceae (Calamus family), e.g. sweetflag or Acorus calamus
36/65 Paeoniaceae (Peony family), e.g. Chinese peony	36/884 Alismataceae (Water-plantain family)
36/66 Papaveraceae (Poppy family), e.g. bloodroot	36/886 Aloeaceae (Aloe family), e.g. aloe vera
36/67 Piperaceae (Pepper family), e.g. Jamaican pepper or kava	36/888 Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
36/68 Plantaginaceae (Plantain Family)	36/8884 Arisaema, e.g. Jack in the pulpit
36/69 Polygalaceae (Milkwort family)	36/8888 Pinellia
36/70 Polygonaceae (Buckwheat family), e.g. spineflower or dock	36/889 Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
36/704 Polygonum, e.g. knotweed	36/8895 Calamus, e.g. rattan
36/708 Rheum (rhubarb)	36/89 Cyperaceae (Sedge family)
36/71 Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal	36/8905 Cyperus (flatsedge)
36/714 Aconitum (monkshood)	36/894 Dioscoreaceae (Yam family)
36/716 Clematis (leather flower)	36/8945 Dioscorea, e.g. yam, Chinese yam or water yam
36/718 Coptis (goldthread)	36/896 Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
36/72 Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree	36/8962 Allium, e.g. garden onion, leek, garlic or chives
36/725 Ziziphus, e.g. jujube	36/8964 Anemarrhena
36/73 Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn	36/8965 Asparagus, e.g. garden asparagus or asparagus fern
36/732 Chaenomeles, e.g. flowering quince	36/8966 Fritillaria, e.g. checker lily or mission bells
36/734 Crataegus (hawthorn)	36/8967 Lilium, e.g. tiger lily or Easter lily
36/736 Prunus, e.g. plum, cherry, peach, apricot or almond	36/8968 Ophiopogon (Lilyturf)
36/738 Rosa (rose)	36/8969 Polygonatum (Solomon's seal)
36/739 Sanguisorba (burnet)	36/898 Orchidaceae (Orchid family)
36/74 Rubiaceae (Madder family)	36/8984 Dendrobium
36/744 Gardenia	36/8988 Gastrodia
36/746 Morinda	36/899 Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
36/748 Oldenlandia or Hedyotis	36/8994 Coix (Job's tears)
36/75 Rutaceae (Rue family)	36/8998 Hordeum (barley)
36/752 Citrus, e.g. lime, orange or lemon	36/90 Smilacaceae (Catbrier family), e.g. greenbrier or sarsaparilla
36/754 Evodia	36/902 Sparganiaceae (Bur-reed family)
36/756 Phellodendron, e.g. corktree	36/904 Stemonaceae (Stemona family), e.g. croomia
36/758 Zanthoxylum, e.g. pricklyash	36/906 Zingiberaceae (Ginger family)
36/76 Salicaceae (Willow family), e.g. poplar	36/9062 Alpinia, e.g. red ginger or galangal
36/77 Sapindaceae (Soapberry family), e.g. lychee or soapberry	36/9064 Amomum, e.g. round cardamom
36/78 Saururaceae (Lizard's-tail family)	36/9066 Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
36/79 Schisandraceae (Schisandra family)	36/9068 Zingiber, e.g. garden ginger
36/80 Scrophulariaceae (Figwort family)		
36/804 Rehmannia		
36/808 Scrophularia (figwort)		
36/81 Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed		
36/815 Lycium (desert-thorn)		
36/82 Theaceae (Tea family), e.g. camellia		
36/83 Thymelaeaceae (Mezereum family), e.g. leatherwood or false ohelo		
36/835 Aquilaria		

38/00 Medicinal preparations containing peptides
(peptides containing beta-lactam rings [A61K 31/00](#); cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, [A61K 31/00](#); ergot alkaloids of the cyclic peptide type [A61K 31/48](#); containing macromolecular compounds having statistically distributed amino acid units [A61K 31/74](#); medicinal preparations containing antigens or antibodies [A61K 39/00](#); medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, [A61K 47/00](#))

NOTES

1. The terms or expressions used in this group follow exactly the definitions given in Note (1) following the title of subclass [C07K](#).
2. Preparations containing fragments of peptides or peptides modified by removal or addition of amino acids, by substitution of amino acids by others, or by combination of these modifications are classified as the preparations containing parent peptides. However, preparations containing fragments of peptides having only four or less amino acids are also classified in groups [A61K 38/05](#) - [A61K 38/07](#).
3. Preparations containing peptides prepared by recombinant DNA technology are not classified according to the host, but according to the original peptide expressed, e.g. preparations containing HIV peptide expressed in E. coli are classified with the preparations containing HIV peptides.
4. This group covers also medicinal preparation containing DNA or RNA encoding for peptides as active ingredient.
5. Documents relating to new peptides, e.g. enzymes, or new DNA or RNA encoding for peptides and their use in medicinal preparations are classified in subclass [C07K](#) or in group [C12N 9/00](#) according to the peptides, with the appropriate indexing codes relating to their medical uses.

- 38/005 . {Enzyme inhibitors (protease inhibitors [A61K 38/55](#))}
- 38/01 . Hydrolysed proteins; Derivatives thereof
- 38/011 . . {from plants}
- 38/012 . . {from animals}
- 38/014 . . . {from connective tissue peptides, e.g. gelatin, collagen}
- 38/015 {from keratin}
- 38/017 . . . {from blood}
- 38/018 . . . {from milk}
- 38/02 . Peptides of undefined number of amino acids; Derivatives thereof
- 38/03 . Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
- 38/04 . Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof ({enzyme inhibitors [A61K 38/005](#)}; gastrins [A61K 38/2207](#); somatostatins [A61K 38/31](#), melanotropins [A61K 38/34](#); {protease inhibitors [A61K 38/55](#)})
- 38/043 . . {Kallidins; Bradykinins; Related peptides}
- 38/046 . . {Tachykinins, e.g. eledoisins, substance P; Related peptides}

- 38/05 . . Dipeptides
- 38/06 . . Tripeptides
- 38/063 . . . {Glutathione}
- 38/066 . . . {TRH, thyroliberin, thyrotropin releasing hormone}
- 38/07 . . Tetrapeptides
- 38/08 . . Peptides having 5 to 11 amino acids
{([A61K 38/043](#) - [A61K 38/046](#) take precedence)}

WARNING

Group [A61K 38/08](#) is impacted by reclassification into group [A61K 38/095](#).

All groups listed in this Warning should be considered in order to perform a complete search.

- 38/085 . . . {Angiotensins}
- 38/09 . . . Luteinising hormone-releasing hormone [LHRH] {, i.e. Gonadotropin-releasing hormone [GnRH]}; Related peptides
- 38/095 . . . Oxytocins; Vasopressins; Related peptides

WARNING

Group [A61K 38/095](#) is incomplete pending reclassification of documents from group [A61K 38/08](#).

Groups [A61K 38/095](#) and [A61K 38/08](#) should be considered in order to perform a complete search.

- 38/10 . . Peptides having 12 to 20 amino acids
{([A61K 38/043](#) - [A61K 38/046](#) take precedence)}
- 38/105 . . . {Bombesin; Related peptides}
- 38/12 . . Cyclic peptides {, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
([A61K 38/043](#) - [A61K 38/046](#) take precedence)}
- 38/13 . . . Cyclosporins
- 38/14 . . Peptides containing saccharide radicals; Derivatives thereof {, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin}
- 38/15 . . Dipeptides; Derivatives thereof
- 38/16 . Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
{(enzyme inhibitors [A61K 38/005](#))}
- 38/162 . . {from virus}
- 38/164 . . {from bacteria}
- 38/166 . . . {Streptokinase}
- 38/168 . . {from plants}
- 38/17 . . from animals; from humans {(enzyme inhibitors [A61K 38/005](#))}
- 38/1703 . . . {from vertebrates ([A61K 38/1767](#) takes precedence)}
- 38/1706 {from fish}
- 38/1709 {from mammals}
- 38/1712 {Not used, see subgroup}
- 38/1716 {Amyloid plaque core protein}
- 38/1719 {Muscle proteins, e.g. myosin, actin}
- 38/1722 {Plasma globulins, lactoglobulin}
- 38/1725 {Complement proteins, e.g. anaphylatoxin, C3a, C5a}
- 38/1729 {Cationic antimicrobial peptides, e.g. defensins}
- 38/1732 {Lectins}
- 38/1735 {Mucins, e.g. human intestinal mucin}

38/1738 {Calcium binding proteins, e.g. calmodulin}
 38/1741 {alpha-Glycoproteins}
 38/1745 {C-reactive protein}
 38/1748 {Keratin; Cytokeratin}
 38/1751 {Bactericidal/permeability-increasing protein [BPI]}
 38/1754 {Insulin-like growth factor binding protein}
 38/1758 {p53}
 38/1761 {Apoptosis related proteins, e.g. Apoptotic protease-activating factor-1 (APAF-1), Bax, Bax-inhibitory protein(s)(BI; bax-I), Myeloid cell leukemia associated protein (MCL-1), Inhibitor of apoptosis [IAP], Bcl-2}

38/1764 {Tumor specific antigens; Tumor rejection antigen precursors [TRAP], e.g. MAGE}

WARNING

Group [A61K 38/1764](#) is no longer used for the classification of documents as of August 1, 2018. The content of this group is being reclassified into groups [A61K 39/0011](#), [A61K 39/001102](#), [A61K 39/001103](#), [A61K 39/001104](#), [A61K 39/001106](#), [A61K 39/001107](#), [A61K 39/001108](#), [A61K 39/001109](#), [A61K 39/00111](#), [A61K 39/001111](#), [A61K 39/001112](#), [A61K 39/001113](#), [A61K 39/001114](#), [A61K 39/001116](#), [A61K 39/001117](#), [A61K 39/001118](#), [A61K 39/001119](#), [A61K 39/00112](#), [A61K 39/001121](#), [A61K 39/001122](#), [A61K 39/001124](#), [A61K 39/001126](#), [A61K 39/001128](#), [A61K 39/001129](#), [A61K 39/00113](#), [A61K 39/001131](#), [A61K 39/001132](#), [A61K 39/001133](#), [A61K 39/001134](#), [A61K 39/001135](#), [A61K 39/001136](#), [A61K 39/001138](#), [A61K 39/001139](#), [A61K 39/00114](#), [A61K 39/001141](#), [A61K 39/001142](#), [A61K 39/001144](#), [A61K 39/001148](#), [A61K 39/001149](#), [A61K 39/00115](#), [A61K 39/001151](#), [A61K 39/001152](#), [A61K 39/001153](#), [A61K 39/001154](#), [A61K 39/001156](#), [A61K 39/001157](#), [A61K 39/001158](#), [A61K 39/001159](#), [A61K 39/00116](#), [A61K 39/001161](#), [A61K 39/001162](#), [A61K 39/001163](#), [A61K 39/001164](#), [A61K 39/001166](#), [A61K 39/001168](#), [A61K 39/001169](#), [A61K 39/00117](#), [A61K 39/001171](#), [A61K 39/001172](#), [A61K 39/001173](#), [A61K 39/001174](#), [A61K 39/001176](#), [A61K 39/001178](#), [A61K 39/00118](#), [A61K 39/001181](#), [A61K 39/001182](#), [A61K 39/001184](#), [A61K 39/001186](#), [A61K 39/001188](#), [A61K 39/001189](#), [A61K 39/00119](#), [A61K 39/001191](#), [A61K 39/001192](#), [A61K 39/001193](#), [A61K 39/001194](#), [A61K 39/001195](#), [A61K 39/001196](#), [A61K 39/001197](#), [A61K 39/001198](#), [A61K 2039/80](#), [A61K 2039/804](#), [A61K 2039/812](#), [A61K 2039/82](#), [A61K 2039/828](#), [A61K 2039/836](#), [A61K 2039/844](#), [A61K 2039/852](#), [A61K 2039/86](#), [A61K 2039/868](#), [A61K 2039/876](#), [A61K 2039/884](#), and [A61K 2039/892](#).

All groups listed in this Warning should be considered in order to perform a complete search.

38/1767 . . . {from invertebrates}
 38/177 . . . {Receptors; Cell surface antigens; Cell surface determinants}
 38/1774 {Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)}

38/1777 {Integrin superfamily}	38/2221 {Relaxins}
38/178 {Lectin superfamily, e.g. selectins}	38/2228 {Corticotropin releasing factor [CRF] (Urotensin)}
38/1783 {Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors}	38/2235 {Secretins}
38/1787 {for neuromediators, e.g. serotonin receptor, dopamine receptor}	38/2242 {Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin}
38/179 {for growth factors; for growth regulators}	38/225 {Calcitonin gene related peptide}
38/1793 {for cytokines; for lymphokines; for interferons}	38/2257 {Prolactin}
38/1796 {for hormones (for neuromediators A61K 38/1787)}	38/2264 {Obesity-gene products, e.g. leptin}
38/18	. . . Growth factors; Growth regulators	38/2271 {Neuropeptide Y}
38/1808 {Epidermal growth factor [EGF] urogastrone}	38/2278 {Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)}
38/1816 {Erythropoietin [EPO]}	38/2285 {Endothelin, vasoactive intestinal contractor [VIC]}
38/1825 {Fibroblast growth factor [FGF]}	38/2292 {Thymosin; Related peptides}
38/1833 {Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II}	38/23 Calcitonins
38/1841 {Transforming growth factor [TGF]}	38/24 Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
38/185 {Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3}	38/25 Growth hormone-releasing factor [GH-RF] (Somatoliberin)
38/1858 {Platelet-derived growth factor [PDGF]}	38/26 Glucagons
38/1866 {Vascular endothelial growth factor [VEGF]}	38/27 Growth hormone [GH] (Somatotropin)
38/1875 {Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor}	38/28 Insulins
38/1883 {Neuregulins, e.g. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor}	38/29 Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
38/1891 {Angiogenesis factors; Angiogenin}	38/30 Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2 (insulin-like growth factor binding protein A61K 38/1754)}
38/19	. . . Cytokines; Lymphokines; Interferons	38/31 Somatostatins
38/191 {Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta}	38/32 Thymopoietins
38/193 {Colony stimulating factors [CSF]}	38/33	. . . derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
38/195 {Chemokines, e.g. RANTES}	38/34 Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
38/196 {Thrombopoietin}	38/35 Corticotropin [ACTH]
38/20 Interleukins [IL]	38/36	. . . Blood coagulation or fibrinolysis factors
38/2006 {IL-1}	38/363 {Fibrinogen}
38/2013 {IL-2}	38/366 {Thrombomodulin}
38/202 {IL-3}	38/37 Factors VIII
38/2026 {IL-4}	38/38 Albumins
38/2033 {IL-5}	38/385 {Serum albumin}
38/204 {IL-6}	38/39	. . . Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
38/2046 {IL-7}	38/395	. . . {Alveolar surfactant peptides; Pulmonary surfactant peptides}
38/2053 {IL-8}	38/40	. . . Transferrins, e.g. lactoferrins, ovotransferrins
38/206 {IL-9}	38/41	. . . Porphyrin- or corrin-ring-containing peptides
38/2066 {IL-10}	38/415	. . . {Cytochromes}
38/2073 {IL-11}	38/42	. . . Haemoglobins; Myoglobins
38/208 {IL-12}	38/43	. . . Enzymes; Proenzymes; Derivatives thereof
38/2086 {IL-13 to IL-16}		
38/2093 {Leukaemia inhibitory factor [LIF]}		
38/21 Interferons {[IFN]}		
38/212 {IFN-alpha}		
38/215 {IFN-beta}		
38/217 {IFN-gamma}		
38/22	. . . Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin A61K 38/33 , e.g. corticotropin A61K 38/35)		
38/2207 {Gastrins; Cholecystokinins [CCK]}		
38/2214 {Motilins}		

NOTE

In this group,

1. proenzymes are classified with the corresponding enzymes;
2. enzymes are generally categorised according to the "Nomenclature and Classification of Enzymes" of the International Commission of Enzymes.

A61K

A61K 38/43

(continued)

- Where appropriate, this designation appears in the subgroups below in parenthesis.
- the specific enzyme(s) used are additionally classified in [C12Y](#).

- 38/44 . . . Oxidoreductases (1)
- 38/443 {acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)}
- 38/446 {Superoxide dismutase (1.15)}
- 38/45 . . . Transferases (2)
- 38/46 . . . Hydrolases (3)
- 38/465 {acting on ester bonds (3.1), e.g. lipases, ribonucleases}
- 38/47 acting on glycosyl compounds (3.2), e.g. cellulases, lactases
- 38/48 acting on peptide bonds (3.4)
- 38/4806 {from animals other than mammals, e.g. snakes}
- 38/4813 {Exopeptidases (3.4.11. to 3.4.19)}
- 38/482 {Serine endopeptidases (3.4.21)}
- 38/4826 {Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)}
- 38/4833 {Thrombin (3.4.21.5)}
- 38/484 {Plasmin (3.4.21.7)}
- 38/4846 {Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)}
- 38/4853 {Kallikrein (3.4.21.34 or 3.4.21.35)}
- 38/486 {Elastase (3.4.21.36 or 3.4.21.37)}
- 38/4866 {Protein C (3.4.21.69)}
- 38/4873 {Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H}
- 38/488 {Aspartic endopeptidases (3.4.23), e.g. pepsin, chymosin, renin, cathepsin E}
- 38/4886 {Metalloendopeptidases (3.4.24), e.g. collagenase}
- 38/4893 {Botulinum neurotoxin (3.4.24.69)}
- 38/49 Urokinase; Tissue plasminogen activator
- 38/50 acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
- 38/51 . . . Lyases (4)
- 38/52 . . . Isomerases (5)
- 38/53 . . . Ligases (6)
- 38/54 . . . Mixtures of enzymes or proenzymes covered by more than a single one of groups [A61K 38/44](#) - [A61K 38/46](#) or [A61K 38/51](#) - [A61K 38/53](#)
- 38/55 . . Protease inhibitors
- 38/553 . . . {Renin inhibitors}
- 38/556 . . . {Angiotensin converting enzyme inhibitors}
- 38/56 . . . from plants
- 38/57 . . . from animals; from humans {([A61K 38/553](#), [A61K 38/556](#) take precedence)}
- 38/58 from leeches, e.g. hirudin, eglin

39/00 Medicinal preparations containing antigens or antibodies (materials for immunoassay [G01N 33/53](#))

NOTES

- Groups [A61K 39/002](#) - [A61K 39/295](#) cover preparations containing protozoa, bacteria, viruses, or subunits thereof, e.g. membrane parts.

- Preparation of antigen or antibody compositions is also classified in subclass [C12N](#), if the step of cultivating the microorganism is of interest.
- Documents relating to new peptides, e.g. enzymes, or new DNA or RNA encoding for peptides and their use in medicinal preparations are classified in subclass [C07K](#) or in group [C12N 9/00](#) according to the peptides, with the appropriate indexing codes relating to their medical uses.
- Documents relating to antibodies or DNA or RNA encoding for antibodies and their use in medicinal preparations are classified in group [C07K 16/00](#) or in group [C12N 9/0002](#) according to the antibodies, with the appropriate indexing codes relating to their medical uses.
- Documents relating to new therapeutical uses of antibodies or DNA or RNA encoding for antibodies are classified in group [C07K 16/00](#) or in group [C12N 9/0002](#) according to the antibodies, with the appropriate indexing codes relating to their medical uses.
- Documents relating to medicinal preparations containing different antibodies as active ingredients are classified in group [C07K 16/00](#) according to the different active antibodies, with the appropriate indexing codes relating to their medical uses. However, documents relating to medicinal preparations containing antibodies and other compounds as active ingredients are classified in groups [A61K 39/395](#) - [A61K 39/42](#), in association with symbol [A61K 2300/00](#) in Combination Sets.

- 39/0001 . {Archaeal antigens}
- 39/0002 . {Fungal antigens, e.g. Trichophyton, Aspergillus, Candida}
- 39/0003 . {Invertebrate antigens}
- 39/0005 . {Vertebrate antigens (from snakes [A61K 39/38](#))}
- 39/0006 . . {Contraceptive vaccins; Vaccines against sex hormones}
- 39/0007 . . {Nervous system antigens; Prions}
- 39/0008 . . {Antigens related to auto-immune diseases; Preparations to induce self-tolerance}
- 39/001 . . {Preparations to induce tolerance to non-self, e.g. prior to transplantation}

39/0011 . . {Cancer antigens}

WARNING

Group [A61K 39/0011](#) is incomplete pending reclassification of documents from group [A61K 38/1764](#). Group [A61K 39/0011](#) is also impacted by reclassification into groups [A61K 39/001102](#), [A61K 39/001103](#), [A61K 39/001104](#), [A61K 39/001106](#), [A61K 39/001107](#), [A61K 39/001108](#), [A61K 39/001109](#), [A61K 39/00111](#), [A61K 39/001111](#), [A61K 39/001112](#), [A61K 39/001113](#), [A61K 39/001114](#), [A61K 39/001116](#), [A61K 39/001117](#), [A61K 39/001118](#), [A61K 39/001119](#), [A61K 39/00112](#), [A61K 39/001121](#), [A61K 39/001122](#), [A61K 39/001124](#), [A61K 39/001126](#), [A61K 39/001128](#), [A61K 39/001129](#), [A61K 39/00113](#), [A61K 39/001131](#), [A61K 39/001132](#), [A61K 39/001133](#), [A61K 39/001134](#), [A61K 39/001135](#), [A61K 39/001136](#), [A61K 39/001138](#), [A61K 39/001139](#), [A61K 39/00114](#), [A61K 39/001141](#), [A61K 39/001142](#), [A61K 39/001144](#), [A61K 39/001148](#), [A61K 39/001149](#), [A61K 39/00115](#), [A61K 39/001151](#), [A61K 39/001152](#), [A61K 39/001153](#), [A61K 39/001154](#), [A61K 39/001156](#), [A61K 39/001157](#), [A61K 39/001158](#), [A61K 39/001159](#), [A61K 39/00116](#), [A61K 39/001161](#), [A61K 39/001162](#), [A61K 39/001163](#), [A61K 39/001164](#), [A61K 39/001166](#), [A61K 39/001168](#), [A61K 39/001169](#), [A61K 39/00117](#), [A61K 39/001171](#), [A61K 39/001172](#), [A61K 39/001173](#), [A61K 39/001174](#), [A61K 39/001176](#), [A61K 39/001178](#), [A61K 39/00118](#), [A61K 39/001181](#), [A61K 39/001182](#), [A61K 39/001184](#), [A61K 39/001186](#), [A61K 39/001188](#), [A61K 39/001189](#), [A61K 39/00119](#), [A61K 39/001191](#), [A61K 39/001192](#), [A61K 39/001193](#), [A61K 39/001194](#), [A61K 39/001195](#), [A61K 39/001196](#), [A61K 39/001197](#), [A61K 39/001198](#), [A61K 2039/80](#), [A61K 2039/804](#), [A61K 2039/812](#), [A61K 2039/82](#), [A61K 2039/828](#), [A61K 2039/836](#), [A61K 2039/844](#), [A61K 2039/852](#), [A61K 2039/86](#), [A61K 2039/868](#), [A61K 2039/876](#), [A61K 2039/884](#), and [A61K 2039/892](#).

All groups listed in this Warning should be considered in order to perform a complete search.

39/001102 . . . {Receptors, cell surface antigens or cell surface determinants}

WARNING

Groups [A61K 39/001102](#) -[A61K 39/001198](#) are incomplete pending reclassification of documents from group [A61K 39/0011](#).

Groups [A61K 38/1764](#), [A61K 39/0011](#), and [A61K 39/001102](#)-[A61K 39/001198](#) and [A61K 39/001102](#) should be considered in order to perform a complete search.

39/001103 {Receptors for growth factors}
 39/001104 {Epidermal growth factor receptors [EGFR]}
 39/001106 {Her-2/neu/ErbB2, Her-3/ErbB3, Her 4/ErbB4}
 39/001107 {Fibroblast growth factor receptors [FGFR]}
 39/001108 {Platelet-derived growth factor receptors [PDGFR]}
 39/001109 {[Vascular endothelial growth factor receptors [VEGFR]}
 39/00111 {Hepatocyte growth factor receptor [HGFR or c-met]}
 39/001111 {Immunoglobulin superfamily}
 39/001112 {CD19, B4}
 39/001113 {CD22, BL-CAM, siglec-2, sialic acid-binding Ig-related lectin 2}
 39/001114 {CD74, Ii, MHC class II invariant chain, MHC class II gamma chain}
 39/001116 {Receptors for cytokines}
 39/001117 {Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30}
 39/001118 {Receptors for colony stimulating factors [CSF]}
 39/001119 {Receptors for interleukins [IL]}
 39/00112 {Receptors for interferons [IFN]}
 39/001121 {Receptors for chemokines }
 39/001122 {Ephrin Receptors [Eph]}
 39/001124 {CD20}
 39/001126 {CD38 not IgG}
 39/001128 {CD44 not IgG}
 39/001129 {Molecules with a "CD" designation not provided for elsewhere}
 39/00113 . . . {Growth factors}
 39/001131 {Epidermal growth factor [EGF]}
 39/001132 {Fibroblast growth factors [FGF]}
 39/001133 {Platelet-derived growth factor [PDGF]}
 39/001134 {Transforming growth factor [TGF]}
 39/001135 {Vascular endothelial growth factor [VEGF]}
 39/001136 . . . {Cytokines}
 39/001138 {Tumor necrosis factors [TNF], CD70}
 39/001139 {Colony stimulating factors [CSF]}
 39/00114 {Interleukins [IL]}
 39/001141 {Interferons [IFN]}
 39/001142 {Chemokines}
 39/001144 . . . {Hormones, e.g. calcitonin}
 39/001148 . . . {Regulators of development}
 39/001149 {Cell cycle regulated proteins, e.g. cyclin, CDC, CDK, INK-CCR}

39/00115 {Apoptosis related proteins, e.g. survivin, livin}	39/005	. . Trypanosoma antigens
39/001151 {p53}	39/008	. . Leishmania antigens
39/001152	. . . {Transcription factors, e.g. SOX, c-MYC}	39/012	. . Coccidia antigens
39/001153 {Wilms tumor 1 [WT1]}	39/015	. . Hemosporidia antigens, e.g. Plasmodium antigens
39/001154	. . . {Enzymes}	39/018	. . . Babesia antigens, e.g. Theileria antigens
39/001156 {Tyrosinase and tyrosinase related proteinases [TRP-1, TRP-2]}	39/02	. Bacterial antigens
39/001157 {Telomerase, TERT [telomerase reverse transcriptase]}	39/0208	. . {Specific bacteria not otherwise provided for}
39/001158 {Proteinases}	39/0216	. . {Bacterioidetes, e.g. Bacteroides, Ornithobacter, Porphyromonas}
39/001159 {Matrix metalloproteinases [MMP]}	39/0225	. . {Spirochetes, e.g. Treponema, Leptospira, Borrelia}
39/00116 {Serine proteases, e.g. kallikrein}	39/0233	. . {Rickettsiales, e.g. Anaplasma}
39/001161 {Caspases}	39/0241	. . {Mollicutes, e.g. Mycoplasma, Erysipelothrix}
39/001162 {Kinases, e.g. Raf, Src}	39/025	. . {Enterobacteriales, e.g. Enterobacter}
39/001163 {Phosphatases}	39/0258	. . . {Escherichia}
39/001164 {GTPases, e.g. Ras, Rho}	39/0266	. . . {Klebsiella}
39/001166	. . . {Adhesion molecules, e.g. NRCAM, EpCAM, cadherins}	39/0275	. . . {Salmonella}
39/001168 {Mesothelin [MSLN]}	39/0283	. . . {Shigella}
39/001169	. . . {Tumor associated carbohydrates}	39/0291	. . . {Yersinia}
39/00117 {Mucins, e.g. MUC-1}	39/04	. . Mycobacterium, e.g. Mycobacterium tuberculosis
39/001171 {Gangliosides, e.g. GM2, GD2, GD3}	39/05	. . {Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella}, Corynebacterium; Propionibacterium { Mycobacterium A61K 39/04 }
39/001172 {sialyl Thomson-nouvelle antigen [sTN]}	39/07	. . Bacillus
39/001173 {Globo-H}	39/08	. . Clostridium, e.g. Clostridium tetani
39/001174	. . . {Proteoglycans, e.g. glypican, brevican, CSPG4}	39/085	. . Staphylococcus
39/001176	. . . {Heat shock proteins}	39/09	. . {Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus}, streptococcus
39/001178	. . . {Tumor rejection antigen precursor [TRAP]}	39/092	. . . {Streptococcus}
39/00118	. . . {from embryonic or fetal origin}	39/095	. . Neisseria
39/001181 {Alpha-feto protein}	39/098	. . {Brucella}
39/001182 {Carcinoembryonic antigen [CEA]}	39/099	. . {Bordetella}
39/001184	. . . {Cancer testis antigens, e.g. SSX, BAGE, GAGE, SAGE}	2039/10	. . {Brucella; Bordetella, e.g. Bordetella pertussis; Not used, see subgroups}
39/001186 {MAGE}	39/102	. . {Pasteurellales, e.g. Actinobacillus}, Pasteurella; Haemophilus
39/001188 {NY-ESO}	39/104	. . {Pseudomonadales, e.g.} Pseudomonas
39/001189 {PRAME}	39/1045	. . . {Moraxella}
39/00119	. . . {Melanoma antigens}	39/105	. . {Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter}
39/001191 {Melan-A/MART}	2039/106	. . {Vibrio; Campylobacter; Not used, see subgroups}
39/001192 {Glycoprotein 100 [Gp100]}	39/107	. . {Vibrio}
39/001193	. . . {Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP, PSGR}	39/114	. . Fusobacterium
39/001194 {Prostate specific antigen [PSA]}	39/116	. . Polyvalent bacterial antigens
39/001195 {Prostate specific membrane antigen [PSMA]}		
39/001196	. . . {Fusion proteins originating from gene translocation in cancer cells}		
39/001197 {Breakpoint cluster region-abelson tyrosine kinase [BCR-ABL]}		
39/001198 {Pml-RARalpha}		
39/0012	. . {Lipids; Lipoproteins}		
39/0013	. {Therapeutic immunisation against small organic molecules, e.g. cocaine, nicotine}		
39/0015	. {Combination vaccines based on measles-mumps-rubella}	39/118	. . Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci
39/0016	. {Combination vaccines based on diphtheria-tetanus-pertussis}	39/12	. Viral antigens
39/0017	. . {Combination vaccines based on whole cell diphtheria-tetanus-pertussis}	39/125	. . Picornaviridae, e.g. calicivirus
39/0018	. . {Combination vaccines based on acellular diphtheria-tetanus-pertussis}	39/13	. . . Poliovirus
39/002	. Protozoa antigens	39/135	. . . Foot- and mouth-disease virus
		39/145	. . Orthomyxoviridae, e.g. influenza virus
		39/15	. . Reoviridae, e.g. calf diarrhea virus

WARNING

This group is no longer used for the classification of new documents as from April 1, 2012. The backlog of this group is being continuously reclassified to subgroups of [A61K 39/0016](#) and of [A61K 39/02](#)

- 39/155 . . Paramyxoviridae, e.g. parainfluenza virus
- 39/165 . . . Mumps or measles virus
- 39/17 . . . Newcastle disease virus
- 39/175 . . . Canine distemper virus
- 39/187 . . Hog cholera virus
- 39/193 . . Equine encephalomyelitis virus
- 39/20 . . Rubella virus
- 39/205 . . Rhabdoviridae, e.g. rabies virus
- 39/21 . . Retroviridae, e.g. equine infectious anemia virus
- 39/215 . . Coronaviridae, e.g. avian infectious bronchitis virus
- 39/225 . . . Porcine transmissible gastroenteritis virus
- 39/23 . . Parvoviridae, e.g. feline panleukopenia virus
- 39/235 . . Adenoviridae
- 39/245 . . Herpesviridae, e.g. herpes simplex virus
- 39/25 . . . Varicella-zoster virus
- 39/255 . . . Marek's disease virus
- 39/265 . . . Infectious rhinotracheitis virus
- 39/27 . . . Equine rhinopneumonitis virus
- 39/275 . . Poxviridae, e.g. avipoxvirus
- 39/285 . . . Vaccinia virus or variola virus
- 39/29 . . Hepatitis virus
- 39/292 . . . {Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen}
- 39/295 . . Polyvalent viral antigens ([vaccinia virus or variola virus A61K 39/285](#)); Mixtures of viral and bacterial antigens

WARNING

This group is no longer used for the classification of new documents as from April 1, 2012. The backlog of this group is being continuously reclassified to [A61K 39/0015](#), to subgroups of [A61K 39/0016](#) and of [A61K 39/12](#)

- 39/35 . Allergens
- 39/36 . . from pollen
- 39/38 . Antigens from snakes
- 39/385 . Haptens or antigens, bound to carriers
- 39/39 . characterised by the immunostimulating additives, e.g. chemical adjuvants
- 39/395 . Antibodies ([agglutinins A61K 38/36](#) {; as drug carriers [A61K 47/50](#)}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- 39/39508 . . {from milk, i.e. lactoglobulins}
- 39/39516 . . {from serum, plasma}
- 39/39525 . . . {Purification}
- 39/39533 . . . {against materials from animals}
- 39/39541 . . . {against normal tissues, cells}
- 39/3955 . . . {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- 39/39558 . . . {against tumor tissues, cells, antigens}
- 39/39566 . . . {against immunoglobulins, e.g. anti-idiotypic antibodies}
- 39/39575 . . {against materials from other living beings excluding bacteria and viruses, e.g. protozoa, fungi, plants}
- 39/39583 . . {against materials not provided for elsewhere, e.g. haptens, coenzymes}
- 39/39591 . . {Stabilisation, fragmentation}
- 39/40 . . bacterial
- 39/42 . . viral

- 39/44 . . Antibodies bound to carriers
- 2039/505 . {comprising antibodies}
- 2039/507 . . {Comprising a combination of two or more separate antibodies}
- 2039/51 . {comprising whole cells, viruses or DNA/RNA}
- 2039/515 . . {Animal cells}
- 2039/5152 . . . {Tumor cells}
- 2039/5154 . . . {Antigen presenting cells [APCs], e.g. dendritic cells, macrophages}
- 2039/5156 . . . {expressing foreign proteins}
- 2039/5158 . . . {Antigen-pulsed cells, e.g. T-cells}
- 2039/517 . . {Plant cells}
- 2039/52 . . {Bacterial cells; Fungal cells; Protozoal cells}
- 2039/521 . . . {inactivated (killed)}
- 2039/522 . . . {avirulent or attenuated}
- 2039/523 . . . {expressing foreign proteins}
- 2039/525 . . {Virus}
- 2039/5252 . . . {inactivated (killed)}
- 2039/5254 . . . {avirulent or attenuated}
- 2039/5256 . . . {expressing foreign proteins}
- 2039/5258 . . . {Virus-like particles}
- 2039/53 . . {DNA (RNA) vaccination}
- 2039/54 . {characterised by the route of administration}
- 2039/541 . . {Mucosal route}
- 2039/542 . . . {oral/gastrointestinal}
- 2039/543 . . . {intranasal}
- 2039/544 . . . {to the airways ([intranasal A61K 2039/543](#))}
- 2039/545 . {characterised by the dose, timing or administration schedule}
- 2039/55 . {characterised by the host/recipient, e.g. newborn with maternal antibodies}
- 2039/552 . . {Veterinary vaccine}
- 2039/555 . {characterised by a specific combination antigen/adjuvant}
- 2039/55505 . . {Inorganic adjuvants}
- 2039/55511 . . {Organic adjuvants}
- 2039/55516 . . . {Proteins; Peptides}
- 2039/55522 . . . {Cytokines; Lymphokines; Interferons}
- 2039/55527 {Interleukins}
- 2039/55533 {IL-2}
- 2039/55538 {IL-12}
- 2039/55544 . . . {Bacterial toxins}
- 2039/5555 . . . {Muramyl dipeptides}
- 2039/55555 . . . {Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers}
- 2039/55561 . . . {CpG containing adjuvants; Oligonucleotide containing adjuvants}
- 2039/55566 . . . {Emulsions, e.g. Freund's adjuvant, MF59}
- 2039/55572 . . . {Lipopolysaccharides; Lipid A; Monophosphoryl lipid A}
- 2039/55577 . . . {Saponins; Quil A; QS21; ISCOMS}
- 2039/55583 . . . {Polysaccharides}
- 2039/55588 . . {Adjuvants of undefined constitution}
- 2039/55594 . . . {from bacteria}
- 2039/57 . {characterised by the type of response, e.g. Th1, Th2}
- 2039/572 . . {cytotoxic response}
- 2039/575 . . {humoral response}
- 2039/577 . . {tolerising response}
- 2039/58 . {raising an immune response against a target which is not the antigen used for immunisation}
- 2039/585 . . {wherein the target is cancer}

- 2039/60 . {characteristics by the carrier linked to the antigen}
- 2039/6006 . . {Cells ([recombinantly expressing antigens A61K 2039/5156](#), [A61K 2039/523](#))}
- 2039/6012 . . {Haptens, e.g. di- or trinitrophenyl (DNP, TNP)}
- 2039/6018 . . {Lipids, e.g. in lipopeptides}
- 2039/6025 . . {Nucleotides}
- 2039/6031 . . {Proteins}
- 2039/6037 . . . {Bacterial toxins, e.g. diphtheria toxoid [DT], tetanus toxoid [TT]}
- 2039/6043 . . . {Heat shock proteins}
- 2039/605 . . . {MHC molecules or ligands thereof}
- 2039/6056 . . . {Antibodies}
- 2039/6062 . . . {Muramyl peptides}
- 2039/6068 . . . {Other bacterial proteins, e.g. OMP}
- 2039/6075 . . . {Viral proteins}
- 2039/6081 . . . {Albumin; Keyhole limpet haemocyanin [KLH]}
- 2039/6087 . . {Polysaccharides; Lipopolysaccharides [LPS]}
- 2039/6093 . . {Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine}
- 2039/62 . {characterised by the link between antigen and carrier}
- 2039/622 . . {non-covalent binding}
- 2039/625 . . {binding through the biotin-streptavidin system or similar}
- 2039/627 . . {characterised by the linker}
- 2039/64 . {characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units}
- 2039/645 . . {Dendrimers; Multiple antigen peptides}
- 2039/70 . {Multivalent vaccine}
- 2039/80 . {Vaccine for a specifically defined cancer}

WARNING

Groups [A61K 2039/80](#) - [A61K 2039/892](#) are incomplete pending reclassification of documents from group [A61K 39/0011](#).

Groups [A61K 38/1764](#), [A61K 39/0011](#) and [A61K 2039/80](#) - [A61K 2039/892](#) should be considered in order to perform a complete search.

- 2039/804 . . {Blood cells [leukemia, lymphoma]}
- 2039/812 . . {Breast}
- 2039/82 . . {Colon}
- 2039/828 . . {Stomach}
- 2039/836 . . {Intestine}
- 2039/844 . . {Liver}
- 2039/852 . . {Pancreas}
- 2039/86 . . {Lung}
- 2039/868 . . {kidney}
- 2039/876 . . {Skin, melanoma}
- 2039/884 . . {prostate}
- 2039/892 . . {Reproductive system [uterus, ovaries, cervix, testes]}

41/00 Medicinal preparations obtained by treating materials with wave energy or particle radiation; {Therapies using these preparations} ([A61K 31/59](#) takes precedence; generation of ultrasonic waves [B06B](#); electric discharge tubes [H01J](#))

- 41/0004 . {Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood}
- 41/0009 . {Inactivation or decontamination of a medicinal preparation prior to administration to the animal or human, e.g. : inactivation of viruses or bacteria for vaccines, sterilisation by electromagnetic radiation}

NOTE

See [A61K 41/0019](#) for the specific method; see [A61L 2/0029](#) if the invention lies in the method of sterilization of the medicinal preparation rather than the sterilized medicinal preparation

- 41/0014 . . {by ultrasonic waves}
- 41/0019 . . {by UV, IR, Rx or gamma rays}
- 41/0023 . {Aggression treatment or altering}

NOTE

This groups covers aggression treatment or altering

- of a medicinal preparation prior to administration to the human/animal, e.g. altering a binding specificity of a monoclonal antibody used in a medicinal agent with an oxidizing agent or an electric potential;
- of a tissue/organ prior to graft, e.g. destroying immunodominant epitopes;
- the permeability of cell membranes or biological barriers *in vivo*, e.g. by ultrasound, prior to the administration of a medicinal preparation to the animal/human;
- for inducing the production of stress response proteins or heat shock proteins in order to reduce subsequent response to injuries

- 41/0028 . {Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds}
- 41/0033 . . {Sonodynamic cancer therapy with sonochemically active agents or sonosensitizers, having their cytotoxic effects enhanced through application of ultrasounds ([ultrasound therapy per se A61N 7/00](#))}
- 41/0038 . {Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy ([radiotherapy per se A61N 5/10](#))}
- 41/0042 . {Photocleavage of drugs *in vivo*, e.g. cleavage of photolabile linkers *in vivo* by UV radiation for releasing the pharmacologically-active agent from the administered agent; photothrombosis or photoocclusion}
- 41/0047 . {Sonopheresis, i.e. ultrasonically-enhanced transdermal delivery, electroporation of a pharmacologically active agent}

NOTE

To be classified in [A61K 9/0009](#) when it is in relation to the galenic form

- 41/0052 . {Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy}

- 41/0057 . {Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent}
- 41/0061 . . {5-aminolevulinic acid-based PDT: 5-ALA-PDT involving porphyrins or precursors of protoporphyrins generated *in vivo* from 5-ALA}
- 41/0066 . . {Psoralene-activated UV-A photochemotherapy (PUVA-therapy), e.g. for treatment of psoriasis or eczema, extracorporeal photopheresis with psoralens or fucocoumarins}
- 41/0071 . . {PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines}
- 41/0076 . . {PDT with expanded (metallo)porphyrins, i.e. having more than 20 ring atoms, e.g. texaphyrins, sapphyrins, hexaphyrins, pentaphyrins, porphocyanines}
- 41/008 . . {Two-Photon or Multi-Photon PDT, e.g. with upconverting dyes or photosensitisers}
- 41/0085 . {Mossbauer effect therapy based on mossbauer effect of a material, i.e. re-emission of gamma rays after absorption of gamma rays by the material; selective radiation therapy, i.e. involving re-emission of ionizing radiation upon exposure to a first ionizing radiation}
- 41/009 . {Neutron capture therapy, e.g. using uranium or non-boron material}
- 41/0095 . . {Boron neutron capture therapy, i.e. BNCT, e.g. using boronated porphyrins}
- 45/00 Medicinal preparations containing active ingredients not provided for in groups A61K 31/00 - A61K 41/00**
- 45/05 . {Immunological preparations stimulating the reticulo-endothelial system, e.g. against cancer}
- 45/06 . Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- 47/00 Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient**
- 47/02 . Inorganic compounds
- 47/06 . Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- 47/08 . . containing oxygen, {e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides}
- 47/10 . . . Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- 47/12 . . . Carboxylic acids; Salts or anhydrides thereof
- 47/14 . . . Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- 47/16 . . containing nitrogen, {e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates}
- 47/18 . . . Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- 47/183 {Amino acids, e.g. glycine, EDTA or aspartame}
- WARNING**
- Group [A61K 47/183](#) is impacted by reclassification into groups [A61K 47/20](#), [A61K 47/22](#), [A61K 47/26](#) and [A61K 47/28](#).
- All groups listed in this Warning should be considered in order to perform a complete search.
- 47/186 {Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide}
- WARNING**
- Group [A61K 47/186](#) is impacted by reclassification into groups [A61K 47/20](#), [A61K 47/22](#), [A61K 47/26](#) and [A61K 47/28](#).
- All groups listed in this Warning should be considered in order to perform a complete search.
- 47/20 . . containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
- WARNING**
- Group [A61K 47/20](#) is incomplete pending reclassification of documents from groups [A61K 47/183](#) and [A61K 47/186](#).
- All groups listed in this Warning should be considered in order to perform a complete search.
- 47/22 . . Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- WARNING**
- Group [A61K 47/22](#) is incomplete pending reclassification of documents from groups [A61K 47/183](#) and [A61K 47/186](#).
- All groups listed in this Warning should be considered in order to perform a complete search.
- 47/24 . . containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- 47/26 . . Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- WARNING**
- Group [A61K 47/26](#) is incomplete pending reclassification of documents from groups [A61K 47/183](#) and [A61K 47/186](#).
- All groups listed in this Warning should be considered in order to perform a complete search.

- 47/28 . . Steroids, e.g. cholesterol, bile acids or glycyrrhetic acid
- WARNING**
- Group [A61K 47/28](#) is incomplete pending reclassification of documents from groups [A61K 47/183](#) and [A61K 47/186](#).
- All groups listed in this Warning should be considered in order to perform a complete search.
- 47/30 . Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- 47/32 . Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, [poly\(meth\)acrylates](#), or [polyvinyl pyrrolidone](#)}
- 47/34 . Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers ([A61K 47/10](#) takes precedence)
- 47/36 . Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- 47/38 . . . Cellulose; Derivatives thereof
- 47/40 . . . Cyclodextrins; Derivatives thereof
- 47/42 . Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein ([oligopeptides having up to five amino acids](#) {[A61K 47/183](#)}; [polyamino acids](#) [A61K 47/34](#))
- 47/44 . Oils, fats or waxes according to two or more groups of [A61K 47/02](#)-[A61K 47/42](#); Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin ([synthetic glycerides](#), e.g. [medium-chain triglycerides](#), [A61K 47/14](#))
- 47/46 . Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
- 47/50 . the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- 47/51 . . the non-active ingredient being a modifying agent
- 47/52 . . . the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
- 47/54 . . . the modifying agent being an organic compound
- 47/541 {Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent}
- 47/542 {Carboxylic acids, e.g. a fatty acid or an amino acid}
- 47/543 {Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine}
- 47/544 {Phospholipids}
- 47/545 {Heterocyclic compounds ([A61K 47/558](#) takes precedence)}
- 47/546 {Porphyrines; Porphyrine with an expanded ring system, e.g. texaphyrine}
- 47/547 {Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent}
- 47/548 {Phosphates or phosphonates, e.g. bone-seeking ([phospholipids](#) [A61K 47/544](#))}
- 47/549 {Sugars, nucleosides, nucleotides or nucleic acids}
- 47/55 the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
- 47/551 {one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid}
- 47/552 {one of the codrug's components being an antibiotic}
- 47/554 {the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid}
- 47/555 {pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells}
- 47/556 {enzyme catalyzed therapeutic agent [ECTA]}
- 47/557 {the modifying agent being biotin}
- 47/558 {the modifying agent being a chemiluminescent acceptor}
- 47/559 {Redox delivery systems, e.g. dihydropyridine pyridinium salt redox systems}
- 47/56 . . . the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- 47/58 obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
- 47/585 {Ion exchange resins, e.g. polystyrene sulfonic acid resin}
- 47/59 obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- 47/593 {Polyesters, e.g. PLGA or polylactide-co-glycolide}
- 47/595 {Polyamides, e.g. nylon ([polyamino acids](#) [A61K 47/62](#))}
- 47/60 the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- 47/605 {the macromolecule containing phosphorus in the main chain, e.g. poly-phosphazene}
- 47/61 the organic macromolecular compound being a polysaccharide or a derivative thereof
- 47/62 . . . the modifying agent being a protein, peptide or polyamino acid

47/64 Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K 47/65)	47/6809 {Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin}
47/641 {Branched, dendritic or hypercomb peptides}	47/6811 {the drug being a protein or peptide, e.g. transferrin or bleomycin}
47/6415 {Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins}	47/6813 {the drug being a peptidic cytokine, e.g. an interleukin or interferon}
47/642 {the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate}	47/6815 {Enzymes}
47/6425 {the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell}	47/6817 {Toxins}
47/643 {Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]}	47/6819 {Plant toxins}
47/6435 {the peptide or protein in the drug conjugate being a connective tissue peptide, e.g. collagen, fibronectin or gelatin}	47/6821 {Plant heterodimeric toxins, e.g. abrin or modeccin}
47/644 {Transferrin, e.g. a lactoferrin or ovotransferrin}	47/6823 {Double chain ricin}
47/6445 {Haemoglobin}	47/6825 {Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin}
47/645 {Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT}	47/6827 {Ricin A}
47/6455 {Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids}	47/6829 {Bacterial toxins, e.g. diptheria toxins or Pseudomonas exotoxin A}
47/646 {the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines}	47/6831 {Fungal toxins, e.g. alpha sarcine, mitogillin, zinniol or restrictocin}
47/65 Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers	47/6833 {Viral toxins}
47/66 the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells	47/6835 {the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site}
47/665 {the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems}	47/6839 {the antibody targeting material from viruses}
47/67 {Enzyme prodrug therapy, e.g. gene directed enzyme drug therapy [GDEPT] or VDEPT}	47/6841 {the antibody targeting a RNA virus}
47/68	. . . the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment	47/6843 {the antibody targeting a material from animals or humans}
47/6801 {Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent}	47/6845 {the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon}
47/6803 {Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates}	47/6847 {the antibody targeting a hormone or a hormone-releasing or -inhibiting factor}
47/6805 {the drug being a vinca alkaloid}	47/6849 {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
47/6807 {the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense}	47/6851 {the antibody targeting a determinant of a tumour cell}
		47/6853 {Carcino-embryonic antigens}
		47/6855 {the tumour determinant being from breast cancer cell}
		47/6857 {the tumour determinant being from lung cancer cell}
		47/6859 {the tumour determinant being from liver or pancreas cancer cell}
		47/6861 {the tumour determinant being from kidney or bladder cancer cell}
		47/6863 {the tumour determinant being from stomach or intestines cancer cell}
		47/6865 {the tumour determinant being from skin, nerves or brain cancer cell}
		47/6867 {the tumour determinant being from a cell of a blood cancer}
		47/6869 {the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate}
		47/6871 {the antibody targeting an enzyme}
		47/6873 {the antibody targeting an immunoglobulin; the antibody being an anti-idiotypic antibody}
		47/6875 {the antibody being a hybrid immunoglobulin}

47/6877	{ the antibody being an immunoglobulin containing regions, domains or residues from different species }	47/6915	{ the form being a liposome with polymerisable or polymerized bilayer-forming substances, e.g. polymersomes }
47/6879	{ the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin }	47/6917	{ the form being a lipoprotein vesicle, e.g. HDL or LDL proteins }
47/6881	{ Cluster-antibody conjugates, i.e. the modifying agent consists of a plurality of antibodies covalently linked to each other or of different antigen-binding fragments covalently linked to each other }	47/6919	{ the form being a ribbon or a tubule cochleate }
47/6883	{ Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy }	47/6921	{ the form being a particulate, a powder, an adsorbate, a bead or a sphere }
47/6885	{ the conjugate or the polymer being a starburst, a dendrimer, a cascade }	47/6923	{ the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb }
47/6887	{ Antibody-chelate conjugates using chelates for therapeutic purposes (radioactive substances, e.g. for use in radio diagnosis or radiotherapy, A61K 51/10 ; antibody-chelates for use in MRI A61K 49/14) }	47/6925	{ the form being a microcapsule, nanocapsule, microbubble or nanobubble }
47/6889	{ Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment }	47/6927	{ the form being a solid microparticle having no hollow or gas-filled cores }
47/6891	{ Pre-targeting systems involving an antibody for targeting specific cells }	47/6929	{ the form being a nanoparticle, e.g. an immuno-nanoparticle }
47/6893	{ clearing therapy or enhanced clearance, i.e. using an antibody clearing agents in addition to T-A and D-M }	47/6931	{ the material constituting the nanoparticle being a polymer }
47/6895	{ Rescue therapy; Agonist-antagonist; Antidotes; Targeted rescue or protection, e.g. by folic acid-folinic acid or conjugated to antibodies }	47/6933	{ the polymer being obtained by reactions only involving carbon to carbon, e.g. poly(meth)acrylate, polystyrene, polyvinylpyrrolidone or polyvinylalcohol }
47/6897	{ Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies }	47/6935	{ the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol }
47/6898	{ using avidin- or biotin-conjugated antibodies }	47/6937	{ the polymer being PLGA, PLA or polyglycolic acid }
47/6899	{ Antibody-Directed Enzyme Prodrug Therapy [ADEPT] }	47/6939	{ the polymer being a polysaccharide, e.g. starch, chitosan, chitin, cellulose or pectin }
47/69	the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit	47/6941	{ the form being a granulate or an agglomerate }
47/6901	{ Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors }	47/6943	{ the form being a pill, a tablet, a lozenge or a capsule }
47/6903	{ the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel }	47/6949	{ inclusion complexes, e.g. clathrates, cavities or fullerenes }
47/6905	{ the form being a colloid or an emulsion }	47/6951	{ using cyclodextrin (cyclodextrins used as simple excipients A61K 47/40) }
47/6907	{ the form being a microemulsion, nanoemulsion or micelle }	47/6953	{ the form being a fibre, a textile, a slab or a sheet }
47/6909	{ Micelles formed by phospholipids }	47/6955	{ the form being a plaster, a bandage, a dressing or a patch }
47/6911	{ the form being a liposome }	47/6957	{ the form being a device or a kit, e.g. stents or microdevices }
47/6913	{ the liposome being modified on its surface by an antibody }			
			48/00		Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

NOTES

- In this group the following expression is used with the meaning indicated:
"gene therapy" means in vivo delivery of nucleic acids encoding for peptides by administration of these nucleic acids or by implanting cells transfected ex vivo with the nucleic acids encoding for the peptides.
- Documents relating to new nucleic acids encoding for peptides, e.g. enzymes, and their use in gene therapy are classified in subclass [C07K](#) or in group [C12N 9/00](#) according to the encoded peptides, with

A61K

A61K 48/00
(continued)

- the appropriate indexing codes relating to gene therapy.
- 3. Documents relating to new vectors and their use in gene therapy are classified in groups [C12N 15/85](#) - [C12N 15/90](#) according to the vectors, and the appropriate indexing codes, including those relating to gene therapy.
- 4. Documents describing cells genetically modified to express a gene of interest and their use in gene therapy are classified in [C12N 5/06](#) according to the cells, with the appropriate indexing codes relating to gene therapy.
- 5. Documents relating to new medical uses of peptides *per se*, which peptides may be encoded by nucleic acids, and wherein the nucleic acids may be administered directly or by implanting cells transfected *ex vivo* with the nucleic acids, are classified in the appropriate groups [A61K 38/00](#) or [A61K 39/00](#) according to the encoded peptides, with the indexing codes relating, *inter alia*, to gene therapy.
- 48/0008 . {characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition}
- 48/0016 . . {wherein the nucleic acid is delivered as a 'naked' nucleic acid, i.e. not combined with an entity such as a cationic lipid}
- 48/0025 . . {wherein the non-active part clearly interacts with the delivered nucleic acid}
- 48/0033 . . . {the non-active part being non-polymeric}
- 48/0041 . . . {the non-active part being polymeric}
- 48/005 . {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- 48/0058 . . {Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a construct}
- 48/0066 . . {Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid}
- 48/0075 . {characterised by an aspect of the delivery route, e.g. oral, subcutaneous}
- 48/0083 . {characterised by an aspect of the administration regime}
- 48/0091 . {Purification or manufacturing processes for gene therapy compositions}
- 49/00 Preparations for testing *in vivo***
- 49/0002 . {General or multifunctional contrast agents, e.g. chelated agents}
- 49/0004 . {Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions}
- 49/0006 . . {Skin tests, e.g. intradermal testing, test strips, delayed hypersensitivity}
- 49/0008 . . {Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure}
- 49/001 . {Preparation for luminescence or biological staining}
- 49/0013 . . {Luminescence}

- 49/0015 . . . {Phosphorescence}
- 49/0017 . . . {Fluorescence *in vivo*}
- 49/0019 {characterised by the fluorescent group}
- 49/0021 {the fluorescent group being a small organic molecule (oligomeric, polymeric, dendritic molecules: [A61K 49/0019](#))}

NOTE

if this fluorescent group is complexed or covalently linked to a carrier, classification is also made according to the nature of the carrier in the appropriate [A61K 49/005](#) subgroup

- 49/0023 {Di- or triarylmethane dye (xanthene dyes [A61K 49/0041](#))}
- 49/0026 {Acridine dyes}
- 49/0028 {Oxazine dyes}
- 49/003 {Thiazine dyes}
- 49/0032 {Methine dyes, e.g. cyanine dyes}
- 49/0034 {Indocyanine green, i.e. ICG, cardiogreen}
- 49/0036 {Porphyrins (used in photodynamic therapy [A61K 41/0071](#) or [A61K 41/0076](#); used as targeting group or modifying agent for targeting a therapeutic compound [A61K 47/546](#))}
- 49/0039 {Coumarin dyes}
- 49/0041 {Xanthene dyes, used *in vivo*, e.g. administered to a mice, e.g. rhodamines, rose Bengal (*in vivo* [G01N](#))}
- 49/0043 {Fluorescein, used *in vivo*}
- 49/0045 {the fluorescent agent being a peptide or protein used for imaging or diagnosis *in vivo*}
- 49/0047 {Green fluorescent protein [GFP]}
- 49/005 {characterised by the carrier molecule carrying the fluorescent agent}

NOTE

Classification is also made according to the nature of the fluorescent group in the appropriate subgroup of [A61K 49/0019](#)

- 49/0052 {Small organic molecules (oligomers, polymers, dendrimers [A61K 49/0054](#))}
- 49/0054 {Macromolecular compounds, i.e. oligomers, polymers, dendrimers}
- 49/0056 {Peptides, proteins, polyamino acids}
- 49/0058 {Antibodies}
- 49/006 . . {Biological staining of tissues *in vivo*, e.g. methylene blue or toluidine blue O administered in the buccal area to detect epithelial cancer cells, dyes used for delineating tissues during surgery}

NOTE

If the dye used for staining is fluorescent, classification is also given for the appropriate subgroup of [A61K 49/0019](#)

- 49/0063 . . {characterised by a special physical or galenical form, e.g. emulsions, microspheres}

NOTE

Note Classification is also made according to the nature of the luminescent or fluorescent

A61K

A61K 49/0063

(continued)

agent and/or the carrier carrying the fluorescent agent

49/0065 . . . {the luminescent/fluorescent agent having itself a special physical form, e.g. gold nanoparticle}

49/0067 . . . {quantum dots, fluorescent nanocrystals}

NOTE

Quantum dots modified on their surface by an antibody are also classified in [A61K 49/0058](#))

49/0069 . . . {the agent being in a particular physical galenical form}

NOTE

If the physical or galenical form containing a fluorescent agent is modified by a particular agent, classification is also made according to the nature of this agent in the appropriate [A61K 49/005](#) subgroup

49/0071 . . . {solution, solute}

49/0073 . . . {semi-solid, gel, hydrogel, ointment}

49/0076 . . . {dispersion, suspension, e.g. particles in a liquid, colloid, emulsion}

49/0078 . . . {microemulsion, nanoemulsion}

NOTE

Microemulsion means that the dispersed phase is in the form of globules having a diameter above or equal to 1 micrometer. Nanoemulsion means that the dispersed phase is in the form of globules having a diameter below 1 micrometer

49/008 . . . {lipoprotein vesicle, e.g. HDL or LDL proteins}

49/0082 . . . {micelle, e.g. phospholipidic micelle and polymeric micelle}

NOTE

Micelles comprise a monolayer of surfactant molecules that are aggregated head-to-head and tail-to-tail, thus forming a small spherical particle; micelles can be normal, i.e., the surfactant heads are hydrophilic, or inverse

49/0084 . . . {liposome, i.e. bilayered vesicular structure}

NOTE

When the surface of the liposome encapsulating a fluorescent agent and used *in vivo* is functionalised by a modifying agent, classification is also made according to the nature of this modifying agent: e.g. a liposome modified on its surface by a peptide is classified in [A61K 49/0084](#) and [A61K 49/0056](#). Liposomes encapsulating a fluorescent agent, used *in vivo* and modified on their surface by a polymer because they incorporate a polymer-lipid conjugate, are only

additionally classified in [A61K 49/0054](#) if the polymer modifying the lipid is unusual. Liposomes encapsulating a fluorescent agent which are pegylated because they incorporate a pegylated lipid are only classified in [A61K 49/0084](#), not in [A61K 49/0054](#)

49/0086 . . . {Polymersome, i.e. liposome with polymerisable or polymerized bilayered-forming substances}

49/0089 . . . {Particulate, powder, adsorbate, bead, sphere}

49/0091 . . . {Microparticle, microcapsule, microbubble, microsphere, microbead, i.e. having a size or diameter higher or equal to 1 micrometer}

NOTE

When the surface of the microparticle encapsulating a fluorescent agent and used *in vivo* is functionalised by a modifying agent, classification is also made according to the nature of this modifying agent, e.g. a microparticle modified on its surface by a peptide is classified in [A61K 49/0091](#) and [A61K 49/0056](#)

49/0093 . . . {Nanoparticle, nanocapsule, nanobubble, nanosphere, nanobead, i.e. having a size or diameter smaller than 1 micrometer, e.g. polymeric nanoparticle}

49/0095 . . . {Nanotubes}

49/0097 . . . {Cells, viruses, ghosts, red blood cells, viral vectors, used for imaging or diagnosis *in vivo*}

49/04 . . X-ray contrast preparations

NOTE

In the preparation of new organic compounds and their use in X-ray contrast preparations, classification is only made in the relevant subclasses [C07C](#) - [C07J](#) according to the type of compound

49/0404 . . {containing barium sulfate}

49/0409 . . {Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound}

49/0414 . . . {Particles, beads, capsules or spheres}

49/0419 . . . {Microparticles, microbeads, microcapsules, microspheres, i.e. having a size or diameter higher or equal to 1 micrometer}

49/0423 . . . {Nanoparticles, nanobeads, nanospheres, nanocapsules, i.e. having a size or diameter smaller than 1 micrometer}

49/0428 . . . {Surface-modified nanoparticles, e.g. immuno-nanoparticles}

49/0433 . . {containing an organic halogenated X-ray contrast-enhancing agent}

49/0438 . . . {Organic X-ray contrast-enhancing agent comprising an iodinated group or an iodine atom, e.g. iopamidol}

- 49/0442 . . . {Polymeric X-ray contrast-enhancing agent comprising a halogenated group}
- 49/0447 . . . {Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound}
- 49/0452 {Solutions, e.g. for injection}
- 49/0457 {Semi-solid forms, ointments, gels, hydrogels}
- 49/0461 {Dispersions, colloids, emulsions or suspensions}
- 49/0466 {Liposomes, lipoprotein vesicles, e.g. HDL or LDL lipoproteins, phospholipidic or polymeric micelles}
- 49/0471 {Perflubron, i.e. perfluorooctylbromide, C₈F₁₇Br emulsions}
- 49/0476 {Particles, beads, capsules, spheres}
- 49/048 {Microparticles, microbeads, microcapsules, microspheres, i.e. having a size or diameter higher or equal to 1 micrometer}
- 49/0485 {Nanoparticles, nanobeads, nanospheres, nanocapsules, i.e. having a size or diameter smaller than 1 micrometer}
- 49/049 {Surface-modified nanoparticles, e.g. immune-nanoparticles}
- 49/0495 {intended for oral administration}
- 49/06 . Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations

NOTE

characterised only by the (inorganic) MRI-active nucleus, e.g. ¹²⁹Xe

- 49/08 . . characterised by the carrier

NOTE

{characterised by the carrier carrying the MRI-active nucleus, e.g. inorganic carrier}

- 49/085 . . . {conjugated systems}

NOTE

The MRI-active nucleus being complexed to a complex-forming compound (e.g. chelating group) or being covalently linked to a molecule, which being further covalently linked or conjugated to a carrier, e.g. polymer. Classification being also made according to the nature of the carrier, e.g. [Gd³⁺]DOTA-polymer to be classified in [A61K 49/085](#) and in the appropriate [A61K 49/12](#) adequate subgroup

- 49/10 . . . Organic compounds

NOTE

the carrier being an organic compound, e.g. ¹³C-labelled molecule or perfluorinated alkane, used as MRI *in vivo* probe, or a small organic molecule, e.g. a sugar, linked to a Gd-chelate

- 49/101 {the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals}

NOTE

In the [A61K 49/101](#) subgroups, the MRI-active nucleus being complexed to a complex-forming compound, e.g. chelating group. Classification being made according to the nature of this complex-forming agent, if it being either an uncommon or new complexing agent (not the usual DTPA, DOTA, DOTP, etc...groups) that forms the real contribution to the claimed MRI invention, or if it being not conjugated to any further molecule, e.g. which being not conjugated to a polymer, peptide, protein or antibody. In that latter case, the MRI probe being e.g. a paramagnetic metal chelate

- 49/103 {the complex-forming compound being acyclic, e.g. DTPA}

- 49/105 {the metal complex being Gd-DTPA}

- 49/106 {the complex-forming compound being cyclic, e.g. DOTA}

- 49/108 {the metal complex being Gd-DOTA}

- 49/12 Macromolecular compounds

NOTE

the carrier being an organic macromolecular compound, i.e. an oligomeric, polymeric, dendrimeric molecule (not being a peptide, protein, polyamino acid (see [A61K 49/00](#)) or an antibody (see [A61K 49/00](#) or [A61K 49/16](#))

- 49/122 {dimers of complexes or complex-forming compounds}

- 49/124 {dendrimers, dendrons, hyperbranched compounds}

NOTE

Said compounds are either complexes or complex-forming compounds, or they form a backbone to which MRI active nuclei are complexed or covalently linked through chelating groups. In that latter case, the subgroup [A61K 49/085](#) being also given. Dendrimeric, dendronised or hyperbranched polyamino acids used as carriers are also classified in [A61K 49/146](#)

- 49/126 {Linear polymers, e.g. dextran, inulin, PEG}

49/128 {comprising multiple complex or complex-forming groups, being either part of the linear polymeric backbone or being pending groups covalently linked to the linear polymeric backbone}	49/1818	. . . {particles, e.g. uncoated or non-functionalised microparticles or nanoparticles}
	NOTE In that latter case, classification is also made in A61K 49/085		NOTE For nanoparticles, i.e. having a size or diameter smaller than 1 micrometer, the subgroups B82Y 5/00 and B82Y 15/00 are also given
49/14 Peptides, e.g. proteins	49/1821 {coated or functionalised microparticles or nanoparticles}
	NOTE the carrier being a peptide (polyamino acid, A61K 49/146) or protein (not an antibody, see A61K 49/16). If the MRI-active nucleus being linked to the peptide or protein or polyamino acid via a complexing or chelating group, the subgroup A61K 49/085 should also be given. If the peptide or protein or polyamino acid being a dendrimer, a dendron, or hyperbranched, then the A61K 49/124 being also given	49/1824 {coated or functionalised nanoparticles (liposomes A61K 49/1812 ; nanoemulsions A61K 49/1806 ; micelles A61K 49/1809)}
49/143 {the protein being an albumin, e.g. HSA, BSA, ovalbumin}	49/1827 {having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle}
49/146 {the peptide being a polyamino acid, e.g. poly-lysine}	49/183 {having a (super)(para)magnetic core coated or functionalised with an inorganic material or being composed of an inorganic material entrapping the MRI-active nucleus, e.g. silica core doped with a MRI-active nucleus}
49/16 Antibodies; Immunoglobulins; Fragments thereof	49/1833 {having a (super)(para)magnetic core coated or functionalised with a small organic molecule (oligomeric, polymeric, dendrimeric A61K 49/1851)}
	NOTE the protein being an antibody, an immunoglobulin or a fragment thereof. If the MRI-active nucleus being linked to the antibody via a complexing or chelating group, the subgroup A61K 49/085 should also be given	49/1836 {the small organic molecule being a carboxylic acid having less than 8 carbon atoms in the main chain}
49/18	. . characterised by a special physical form, e.g. emulsions, microcapsules, liposomes	49/1839 {the small organic molecule being a lipid, a fatty acid having 8 or more carbon atoms in the main chain, or a phospholipid}
	NOTE Classification being also made according to the molecule complexing or bearing the MRI-active nucleus	49/1842 {the small organic molecule being a phosphate or a phosphonate, not being a phospholipid}
49/1803	. . . {Semi-solid preparations, e.g. ointments, gels, hydrogels}	49/1845 {the small organic molecule being a carbohydrate (monosaccharides, disaccharides)}
49/1806	. . . {Suspensions, emulsions, colloids, dispersions}	49/1848 {the small organic molecule being a silane}
49/1809	. . . {Micelles, e.g. phospholipidic or polymeric micelles}	49/1851 {having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule (peptide or protein A61K 49/1866 ; polyamino acid A61K 49/1872 ; antibody A61K 49/1875)}
49/1812	. . . {liposomes, polymersomes, e.g. immunoliposomes}	49/1854 {the organic macromolecular compound being obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly(meth)acrylate, polyacrylamide, polyvinylpyrrolidone, polyvinylalcohol}
	NOTE If the paramagnetic metal complexes are covalently linked to the bilayered membrane, then the A61K 49/085 subgroup being also given. Liposomes modified on their external surface by a targeting agent, e.g. an antibody are classified in A61K 49/1812 without further indication for the targeting agent		
49/1815	. . . {compo-inhalant, e.g. breath tests}		

- 49/1857 {the organic macromolecular compound being obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. PLGA}
- 49/186 {the organic macromolecular compound being polyethyleneglycol [PEG]}
- 49/1863 {the organic macromolecular compound being a polysaccharide or derivative thereof, e.g. chitosan, chitin, cellulose, pectin, starch}
- 49/1866 {the nanoparticle having a (super) (para)magnetic core coated or functionalised with a peptide, e.g. protein, polyamino acid}
- 49/1869 {coated or functionalised with a protein being an albumin, e.g. HSA, BSA, ovalbumin}
- 49/1872 {coated or functionalised with a polyamino acid, e.g. polylysine, polyglutamic acid}
- 49/1875 {coated or functionalised with an antibody}
- 49/1878 {the nanoparticle having a magnetically inert core and a (super)(para)magnetic coating}
- 49/1881 {wherein the coating consists of chelates, i.e. chelating group complexing a (super)(para)magnetic ion, bound to the surface}
- 49/1884 {Nanotubes, nanorods or nanowires}
- 49/1887 {Agglomerates, clusters, i.e. more than one (super)(para)magnetic microparticle or nanoparticle are aggregated or entrapped in the same matrix}
- 49/189 . . . {Host-guest complexes, e.g. cyclodextrins}
- 49/1893 . . . {Molecular sieves}
- 49/1896 . . . {not provided for elsewhere, e.g. cells, viruses, ghosts, red blood cells, virus capsids}
- 49/20 . . containing free radicals {, e.g. trityl radical for overhauser}
- 49/22 . Echographic preparations; Ultrasound imaging preparation {Optoacoustic imaging preparations}
- 49/221 . . {characterised by the targeting agent or modifying agent linked to the acoustically-active agent}
- 49/222 . . {characterised by a special physical form, e.g. emulsions, liposomes}
- 49/223 . . . {Microbubbles, hollow microspheres, free gas bubbles, gas microspheres}
- 49/225 . . . {Microparticles, microcapsules (gas-filled to be classified in [A61K 49/223](#))}
- 49/226 . . . {Solutes, emulsions, suspensions, dispersions, semi-solid forms, e.g. hydrogels}
- 49/227 . . . {Liposomes, lipoprotein vesicles, e.g. LDL or HDL lipoproteins, micelles, e.g. phospholipidic or polymeric}
- 49/228 . . . {Host-guest complexes, clathrates, chelates}

51/00 Preparations containing radioactive substances for use in therapy or testing in vivo

WARNING

Groups [A61K 51/00](#) - [A61K 51/1296](#) are incomplete pending reclassification of documents from group [A61K 33/24](#).

All groups listed in this Warning should be considered in order to perform a complete search.

- 51/02 . characterised by the carrier {, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus}

- 51/025 . . {inorganic Tc complexes or compounds}

- 51/04 . . Organic compounds

NOTE

Organic compounds used as carriers

- 51/0402 . . . {carboxylic acid carriers, fatty acids (amino acids [A61K 51/0406](#))}

- 51/0404 . . . {Lipids, e.g. triglycerides; Polycationic carriers (polycationic carriers being oligomers, polymers, dendrimers [A61K 47/56](#); fatty acids [A61K 51/0402](#); cholesterol [A61K 51/0493](#))}

- 51/0406 {Amines, polyamines, e.g. spermine, spermidine, amino acids, (bis)guanidines}

- 51/0408 {Phospholipids (liposomes encapsulating the radioactive probe or having no radiolabelled phospholipids [A61K 51/1231](#))}

- 51/041 . . . {Heterocyclic compounds}

NOTE

Under this group, the last place rule is followed

- 51/0412 {having oxygen as the only ring hetero atom, e.g. fungichromin}

- 51/0414 {having three-membered rings, e.g. oxirane, fumagillin}

- 51/0417 {having four-membered rings, e.g. taxol}

- 51/0419 {having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide}

- 51/0421 {having six-membered rings with one oxygen as the only ring hetero atom}

- 51/0423 {having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel}

- 51/0425 {compounds containing methylenedioxyphenol groups, e.g. sesamin}

- 51/0427 {Lactones}

- 51/0429 {having sulfur as a ring hetero atom}

- 51/0431 {having five-membered rings}

- 51/0434 {having six-membered rings, e.g. thioxanthenes (thiotixene [A61K 51/0459](#))}

- 51/0436 {having two or more sulfur atoms in the same ring}

- 51/0438 {having oxygen in the same ring}

- 51/044 {having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins (rifampin [A61K 51/0459](#))}

- 51/0442 {having three-membered rings, e.g. aziridine}

- 51/0444 {having four-membered rings, e.g. azetidine}

- 51/0446 {having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulphiride, succinimide, tolmetin, buflomedil}
- 51/0448 {tropane or nortropane groups, e.g. cocaine}
- 51/0451 {having four such rings, e.g. porphine derivatives, bilirubin, biliverdine ([hemin](#), [hematin](#) [A61K 51/0472](#))}
- NOTE**
- Porphyrins or texaphyrins used as complex-forming compounds, i.e. wherein the nitrogen atoms forming the central ring system complex the radioactive metal, are classified in [A61K 51/0485](#)
- 51/0453 {having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole}
- 51/0455 {having six-membered rings with one nitrogen as the only ring hetero atom}
- 51/0457 {Vesamicol}
- 51/0459 {having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine}
- 51/0461 {having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine ([melarsoprol](#) [A61K 51/0472](#))}
- 51/0463 {having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines}
- 51/0465 {having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame}
- 51/0468 {having seven-membered rings, e.g. azelastine, pentylenetetrazole}
- 51/047 {Benzodiazepines}
- 51/0472 {containing heavy metals, e.g. hemin, hematin, melarsoprol}
- 51/0474 {complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. $^{111}\text{In}^{3+}$) is complexed or chelated by, e.g. a N_2S_2 , N_3S , NS_3 , N_4 chelating group}

NOTE

Classification is made according to the nature of this complex-forming agent, if it is either an uncommon or new complexing agent (not the usual DTPA, DOTA, DOTP, MAG3 etc...groups) that forms the real contribution to the claimed invention (radioimaging or radiotherapeutic agent), or if it is not conjugated to any further molecule, e.g. which is not conjugated to a polymer, peptide, protein or antibody. In that latter case, the radioactive agent is e.g. a radioactive metal chelate

- 51/0476 {complexes from monodendate ligands, e.g. sestamibi}
- 51/0478 {complexes from non-cyclic ligands, e.g. EDTA, MAG3}

- 51/048 {DTPA (diethylenetriamine tetraacetic acid)}
- 51/0482 {chelates from cyclic ligands, e.g. DOTA}
- 51/0485 {Porphyrins, texaphyrins wherein the nitrogen atoms forming the central ring system complex the radioactive metal}

NOTE

Porphyrins used as simple heterocyclic carriers containing a radioactive nucleus (e.g. ^{11}C) or substituted with a radioactive nucleus (e.g. ^{18}F), are classified in [A61K 51/0451](#)

- 51/0487 {Metallocenes, i.e. complexes based on a radioactive metal complexed by two cyclopentadienyl anions}
- 51/0489 {Phosphates or phosphonates, e.g. bone-seeking phosphonates; ([phospholipids](#): [A61K 51/0408](#); [nucleotides or nucleic acids](#): [A61K 51/0491](#))}
- 51/0491 {Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers}
- 51/0493 {Steroids, e.g. cholesterol, testosterone}
- 51/0495 {Pretargeting}

NOTE

Pretargeting is the administration of an agent X bearing the radioisotope or radioactive nucleus and of an agent Y capable of binding X and a cell Y in several steps, e.g. the radiolabelled agent is a radiolabelled biotin and the agent Y is a (strept)avidin molecule targeting specific cells. Classification is also made according to the nature of the carrier bearing/linked to the radioactive nucleus, e.g. an antibody

- 51/0497 {conjugates with a carrier being an organic compounds}

NOTE

The compound which bears, complexes or chelates the radioactive nucleus, is covalently linked or complexed to the carrier being another (small) organic molecule, i.e. not oligomeric, polymeric, dendrimeric. Classification is also made according to the nature of this small organic molecule. In case of a conjugate comprising a complex-forming compound (chelating group) complexing a radioactive metal linked to the carrier (organic compound in [A61K 51/0497](#)), the nature of this complex-forming compound is not classified except if the complexing/chelating group is the subject of the invention and is uncommon, e.g. ^{111}In -DTPA-glucose is classified in [A61K 51/0497](#) (not in [A61K 51/048](#)) and in [A61K 51/0491](#)

- 51/06 Macromolecular compounds {, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules ([peptides](#), [proteins](#), [polyamino acids](#) [A61K 51/08](#); [antibodies](#) [A61K 51/10](#))}

51/065 {conjugates with carriers being macromolecules}	2 and complexing ¹¹¹ In for use <u>in vivo</u> is classified in A61K 51/0478 and A61K 51/088
NOTE		
	The compound which bears, complexes or chelates the radioactive nucleus, is covalently linked or complexed to the carrier being a macromolecule (not being a peptide, polyamino acid, protein, antibody). In case of a conjugate comprising a complex-forming compound (chelating group) complexing a radioactive metal linked to the carrier (organic macromolecular compound in A61K 51/065), the nature of this complex-forming compound is not classified except if it is the real contribution of the claimed invention and it is an uncommon complexing/chelating group, e.g. ¹¹¹ In-DTPA-PEG is classified in A61K 51/065 and new DTPA-like derivatives conjugated to PEG and complexing ¹¹¹ In for use <u>in vivo</u> is classified in A61K 51/0478 and A61K 51/065	
51/08	. . . Peptides, e.g. proteins {, carriers being peptides, polyamino acids, proteins}	
51/081 {the protein being an albumin, e.g. human serum albumin [HSA], bovine serum albumin [BSA], ovalbumin}	
51/082 {the peptide being a RGD-containing peptide}	
51/083 {the peptide being octreotide or a somatostatin-receptor-binding peptide}	
51/084 {the peptide being oxytocin}	
51/085 {the peptide being neurotensin}	
51/086 {the peptide being alphaMSH, alpha melanocyte stimulating hormone}	
51/087 {the peptide being an annexin, e.g. annexin V}	
51/088 {conjugates with carriers being peptides, polyamino acids, proteins (antibodies A61K 51/10)}	
NOTE		
	The compound which bears, complexes or chelates the radioactive nucleus, is covalently linked/complexed to the carrier being a peptide, polyamino acid, protein (not being an antibody). Classification is also made according to the nature of the peptide or protein (e.g. if it is BSA, then A61K 51/081 is also indicated). In case of a conjugate comprising a complex-forming compound (chelating group) complexing a radioactive metal linked to the carrier (peptide, protein, polyamino acid in A61K 51/088), the nature of this complex-forming compound is not classified except if it is the real contribution of the claimed invention and it is an uncommon complexing or chelating group, e.g. ¹¹¹ In-DTPA-interleukin 2 is classified in A61K 51/088 ; new DTPA-like derivatives conjugated to interleukin	
51/10 Antibodies or immunoglobulins; Fragments thereof {, the carrier being an antibody or an immunoglobulin, or a fragment thereof, e.g. a camelised human single domain antibody, or the Fc fragment of an antibody}	
51/1003 {not used, see subgroups}	
51/1006 {the antibody being against or targeting material from viruses}	
51/1009 {against material from bacteria}	
51/1012 {against material from fungi, lichens, algae}	
51/1015 {against material from plants}	
51/1018 {against material from animals or humans}	
51/1021 {against cytokines, e.g. growth factors, VEGF, TNF, lymphokines, interferons}	
51/1024 {against hormones, hormone-releasing or hormone-inhibiting factors}	
51/1027 {against receptors, cell-surface antigens, cell-surface determinants}	
51/103 {against receptors for growth factors or receptors for growth regulators}	
51/1033 {against receptors for cytokines, lymphokines, interferons}	
51/1036 {against hormone receptors}	
51/1039 {against T-cell receptors}	
51/1042 {against Tcell receptor (TcR)-CD3 complex}	
51/1045 {against animal or human tumor cells or tumor cell determinants}	
51/1048 {the tumor cell determinant being a carcino embryonic antigen}	
51/1051 {the tumor cell being from breast, e.g. the antibody being herceptin}	
51/1054 {the tumor cell being from lung}	
51/1057 {the tumour cell being from liver or pancreas}	
51/106 {the tumor cell being from kidney, bladder}	
51/1063 {the tumor cell being from stomach or intestines}	
51/1066 {the tumor cell being from skin}	
51/1069 {the tumor cell being from blood cells, e.g. the cancer being a myeloma}	
51/1072 {the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes, prostate}	
51/1075 {the antibody being against an enzyme}	
51/1078 {the antibody being against an immunoglobulin, i.e. being an (anti)-anti-idiotypic antibody}	
51/1081 {the antibody being against a material not provided elsewhere}	
51/1084 {the antibody being a hybrid immunoglobulin}	
51/1087 {the immunoglobulin comprises domains from different animal species, e.g. chimeric immunoglobulins}	

51/109 {immunoglobulins having two or more different antigen-binding sites, multifunctional antibodies}	antibody, are not additionally classified with the symbol of the targeting agent
51/1093 {conjugates with carriers being antibodies}	51/1237 {Polymersomes, i.e. liposomes with polymerisable or polymerized bilayer-forming substances}
NOTE		
The compound which bears, complexes or chelates the radioactive nucleus, being covalently linked or complexed to the carrier being an antibody Classification being also made according to the appropriate A61K 51/1003 subclass. In case of a conjugate comprising a complex-forming compound (chelating group) complexing a radioactive metal linked to the carrier (antibody in A61K 51/1093), the nature of this complex-forming compound being not classified except if it being the real contribution of the claimed invention and it being an uncommon complexing/chelating group, e.g. ¹¹¹ In-DTPA-herceptin being classified in A61K 51/1093 and A61K 51/1051 , new DTPA-like derivatives conjugated to herceptin and complexing ¹¹¹ In for use <i>in vivo</i> being classified in A61K 51/0478 , A61K 51/1093 and A61K 51/1051		
51/1096 {radioimmunotoxins, i.e. conjugates being structurally as defined in A61K 51/1093 , and including a radioactive nucleus for use in radiotherapeutic applications}	51/1241 . . {particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins}
51/12	. characterised by a special physical form, e.g. emulsion, microcapsules, liposomes {, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules (liposomes A61K 51/1234)}	51/1244 . . . {microparticles or nanoparticles, e.g. polymeric nanoparticles}
51/1203	. . {in a form not provided for by groups A61K 51/1206 - A61K 51/1296 , e.g. cells, cell fragments, viruses, virus capsides, ghosts, red blood cells, viral vectors}	51/1248 {nanotubes}
51/1206	. . {Administration of radioactive gases, aerosols or breath tests}	51/1251 {micro- or nanospheres, micro- or nanobeads, micro- or nanocapsules}
51/121	. . {Solutions, i.e. homogeneous liquid formulation}	51/1255 . . . {Granulates, agglomerates, microspheres}
51/1213	. . {Semi-solid forms, gels, hydrogels, ointments, fats and waxes that are solid at room temperature}	51/1258 . . {Pills, tablets, lozenges}
51/1217	. . {Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols}	51/1262 . . {Capsules}
51/122	. . . {Microemulsions, nanoemulsions}	51/1265 . . . {Microcapsules}
51/1224	. . . {Lipoprotein vesicles, e.g. HDL and LDL proteins}	51/1268 . . {host-guest, closed hollow molecules, inclusion complexes, e.g. with cyclodextrins, clathrates, cavitates, fullerenes}
51/1227	. . . {Micelles, e.g. phospholipidic or polymeric micelles}	51/1272 . . {Sponges}
51/1231	. . . {Aerosols or breath tests, e.g. administration of gasses, emanators}	51/1275 . . {Fibers, textiles, slabs, or sheets}
51/1234	. . . {Liposomes}	51/1279 . . {Plasters, bandages, dressings, patches or adhesives}
NOTE		
Liposomes modified on their external surface by a targeting agent, e.g. an		
		51/1282 . . {Devices used <i>in vivo</i> and carrying the radioactive therapeutic or diagnostic agent, therapeutic or <i>in vivo</i> diagnostic kits, stents}
		51/1286 . . . {Ampoules, glass carriers carrying the therapeutic or <i>in vivo</i> diagnostic agent}
		51/1289 . . . {Devices or containers for impregnation, for emanation, e.g. bottles or jars for radioactive water for use in radiotherapy}
		51/1293 . . {Radioactive cosmetics, e.g. radioactive bathsalts, soaps}
		51/1296 . . {Radioactive food, e.g. chocolates, drinks}
		2121/00 Preparations for use in therapy
		2123/00 Preparations for testing <i>in vivo</i>
		2236/00 Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
		NOTE
		If the isolation or extraction method is considered relevant, at least one symbol of A61K 36/30 should always be given. The method can be further characterized by additional A61K 36/10 and/or A61K 36/50 symbols. The last place priority rule does not apply in this part of the scheme
	2236/10	. Preparation or pretreatment of starting material
	2236/11	. . involving culturing conditions, e.g. cultivation in the dark or under defined water stress
	2236/13	. . involving cleaning, e.g. washing or peeling
	2236/15	. . involving mechanical treatment, e.g. chopping up, cutting or grinding
	2236/17	. . involving drying, e.g. sun-drying or wilting
	2236/19	. . involving fermentation using yeast, bacteria or both; enzymatic treatment (<i>fermentation or enzyme-using processes in general C12P</i>)
	2236/30	. Extraction of the material

2236/31	. . involving untreated material, e.g. fruit juice or sap obtained from fresh plants	2800/41	. . Particular ingredients further characterized by their size
2236/33	. . involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones	2800/412	. . . Microsized, i.e. having sizes between 0.1 and 100 microns
2236/331	. . . using water, e.g. cold water, infusion, tea, steam distillation, decoction (subcritical water extraction A61K 2236/37)	2800/413	. . . Nanosized, i.e. having sizes below 100 nm
2236/333	. . . using mixed solvents, e.g. 70% EtOH	2800/42	. . Colour properties
2236/35	. . Extraction with lipophilic solvents, e.g. Hexane or petrol ether	2800/43	. . . Pigments; Dyes
2236/37	. . Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction	2800/432 Direct dyes
2236/39	. . Complex extraction schemes, e.g. fractionation or repeated extraction steps	2800/4322 in preparations for temporarily coloring the hair further containing an oxidizing agent
2236/50	. Methods involving additional extraction steps	2800/4324 in preparations for permanently dyeing the hair
2236/51	. . Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying	2800/434 Luminescent, Fluorescent; Optical brighteners; Photosensitizers
2236/53	. . Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization	2800/436 Interference pigments, e.g. Iridescent, Pearlescent
2236/55	. . Liquid-liquid separation; Phase separation	2800/437 Diffractive phenomena; Photonic arrays
2300/00	Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K 31/00 - A61K 41/00	2800/438 Thermochromatic; Photochromic; Phototropic
NOTE		2800/45	. . . Colour indicators, e.g. pH- or Redox indicators
This code is meant to be allocated in combination with the CPC classification symbol of the active ingredients, and replaces the former +M Combi symbols used in this subclass		2800/47	. . Magnetic materials; Paramagnetic compounds
2800/00	Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects	2800/48	. . Thickener, Thickening system
NOTE		2800/49	. . Solubiliser, Solubilising system
This subclass is a secondary classification, e.g. obligatory supplementary classification when already classified in group A61K 8/00 or subclass A61Q		2800/51	. . Chelating agents
2800/10	. General cosmetic use	2800/52	. . Stabilizers
2800/20	. Chemical, physico-chemical or functional or structural properties of the composition as a whole	2800/522	. . . Antioxidants; Radical scavengers
2800/21	. . Emulsions characterized by droplet sizes below 1 micron	2800/524	. . . Preservatives
2800/22	. . Gas releasing	2800/526	. . . Corrosion inhibitors
2800/222	. . . Effervescent	2800/54	. . Polymers characterized by specific structures/properties
2800/24	. . Thermal properties	2800/542	. . . characterized by the charge
2800/242	. . . Exothermic; Self-heating; Heating sensation	2800/5422 nonionic
2800/244	. . . Endothermic; Cooling; Cooling sensation	2800/5424 anionic
2800/26	. . Optical properties	2800/5426 cationic
2800/262	. . . Transparent; Translucent	2800/5428 amphoteric or zwitterionic
2800/28	. . Rubbing or scrubbing compositions; Peeling or abrasive compositions; Containing exfoliants	2800/544	. . . Dendrimers, Hyperbranched polymers
2800/30	. . Characterized by the absence of a particular group of ingredients	2800/546	. . . Swellable particulate polymers
2800/31	. . . Anhydrous	2800/548	. . . Associative polymers
2800/33	. . . Free of surfactant	2800/56	. . Compounds, absorbed onto or entrapped into a solid carrier, e.g. encapsulated perfumes, inclusion compounds, sustained release forms
2800/34	. . . Free of silicones	2800/57	. . Compounds covalently linked to a(n inert) carrier molecule, e.g. conjugates, pro-fragrances
2800/40	. Chemical, physico-chemical or functional or structural properties of particular ingredients	2800/58	. . Metal complex; Coordination compounds
		2800/59	. . Mixtures
		2800/591	. . . Mixtures of compounds not provided for by any of the codes A61K 2800/592 - A61K 2800/596
		2800/592	. . . Mixtures of compounds complementing their respective functions
		2800/5922 At least two compounds being classified in the same subclass of A61K 8/18
		2800/594	. . . Mixtures of polymers
		2800/596	. . . Mixtures of surface active compounds
		2800/60	. . Particulates further characterized by their structure or composition
		2800/61	. . . Surface treated
		2800/612 By organic compounds
		2800/614 By macromolecular compounds
		2800/62 Coated
		2800/621 by inorganic compounds
		2800/622 by organic compounds

A61K

- 2800/623 Coating mediated by organosilicone compounds
- 2800/624 by macromolecular compounds
- 2800/63 More than one coating
- 2800/65 . . . Characterized by the composition of the particulate/core
- 2800/651 The particulate/core comprising inorganic material
- 2800/652 The particulate/core comprising organic material
- 2800/654 The particulate/core comprising macromolecular material
- 2800/70 . . Biological properties of the composition as a whole
- 2800/72 . . Hypo-allergenic
- 2800/74 . . Biological properties of particular ingredients
- 2800/75 . . Anti-irritant
- 2800/77 . . Perfumes having both deodorant and antibacterial properties
- 2800/78 . . Enzyme modulators, e.g. Enzyme agonists
- 2800/782 . . . Enzyme inhibitors; Enzyme antagonists
- 2800/80 . . Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- 2800/805 . . Corresponding aspects not provided for by any of codes [A61K 2800/81](#) - [A61K 2800/95](#)
- 2800/81 . . Preparation or application process involves irradiation
- 2800/82 . . Preparation or application process involves sonication or ultrasonication
- 2800/83 . . Electrophoresis; Electrodes; Electrolytic phenomena
- 2800/84 . . Products or compounds obtained by lyophilisation, freeze-drying
- 2800/85 . . Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine
- 2800/86 . . Products or compounds obtained by genetic engineering
- 2800/87 . . Application Devices; Containers; Packaging
- 2800/872 . . . Pencils; Crayons; Felt-tip pens
- 2800/874 . . . Roll-on
- 2800/88 . . Two- or multipart kits
- 2800/882 . . . Mixing prior to application
- 2800/884 . . . Sequential application
- 2800/91 . . Injection
- 2800/92 . . Oral administration
- 2800/94 . . Involves covalent bonding to the substrate
- 2800/95 . . Involves in-situ formation or cross-linking of polymers